

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/053057 A2

(51) International Patent Classification⁷: C12N
(21) International Application Number: PCT/US2003/034563
(22) International Filing Date: 31 October 2003 (31.10.2003)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data: 60/432,651 11 December 2002 (11.12.2002) US
(71) Applicant: 3M INNOVATIVE PROPERTIES COMPANY [US/US]; 3M Center, Post Office Box 33427, Saint Paul, MN 55133-3427 (US).

(72) Inventors: GUPTA, Shalley K.; Post Office Box 33427, Saint Paul, MN 55133-3427 (US). GHOSH, Tarun K.; Post Office Box 33427, Saint Paul, MN 55133-3427 (US). FINK, Jason R.; Post Office Box 33427, Saint Paul, MN 55133-3427 (US).

(74) Agents: GRAM, Christopher D., et al.; Office of Intellectual Property Counsel, Post Office Box 33427, Saint Paul, MN 55133-3427 (US).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,

CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENE EXPRESSION SYSTEMS AND RECOMBINANT CELL LINES

(57) Abstract: The present invention provides gene expression systems useful for detecting agonists of Toll-like receptors. The gene expression systems include a nucleic acid sequence encoding a Toll-like receptor and a second nucleic acid sequence that encodes a reporter operably linked to an expression control sequence. The recombinant cell lines include a gene expression system according to the present invention.



WO 2004/053057 A2

GENE EXPRESSION SYSTEMS AND RECOMBINANT CELL LINES

Background of the Invention

Cells of the immune system secrete a diverse set of compounds including
5 cytokines, chemokines, co-stimulatory markers, and defensins in response to an immunological challenge.

Certain compounds known as immune response modifiers ("IRMs") possess potent immunostimulating activity including but not limited to antiviral and antitumor activity. Certain IRMs effect their immunostimulatory activity by, e.g., inducing the production and
10 secretion of certain cytokines while inhibiting production and secretion of other cytokines. Certain IRMs are small organic molecules such as those disclosed in, for example, U.S. Patent Nos. 4,689,338; 4,929,624; 5,266,575; 5,268,376; 5,352,784; 5,389,640; 5,482,936; 5,494,916; 6,110,929; 6,194,425; 4,988,815; 5,175,296; 5,367,076; 5,395,937; 5,693,811; 5,741,908; 5,238,944; 5,939,090; 6,245,776; 6,039,969; 6,083,969; 6,245,776; 6,331,539;
15 and 6,376,669; and PCT Publications WO 00/76505; WO 00/76518; WO 02/46188, WO 02/46189; WO 02/46190; WO 02/46191; WO 02/46192; WO 02/46193; and WO 02/46194.

Additional small molecule IRMs include purine derivatives (such as those described in U.S. Patent Nos. 6,376,50 and 6,028,076), small heterocyclic compounds
20 (such as those described in U.S. Patent No. 6,329,381), and amide derivatives (such as those described in U.S. Patent No. 6,069,149).

Other IRMs include large biological molecules such as oligonucleotide sequences. Some IRM oligonucleotide sequences contain cytosine-guanine dinucleotides (CpG) and are described, for example, in U.S. Patent Nos. 6,1994,388; 6,207,646; 6,239,116;
25 6,339,068; and 6,406,705. Other IRM nucleotide sequences lack CpG and are described, for example, in International Patent Publication No. WO 00/75304.

Some of these IRMs induce cellular responses (e.g., the production and/or secretion of cytokines, chemokines, etc.) through one or more Toll-like receptors (TLRs). For example, certain small organic molecule IRMs are agonists of one or more of TLR-1,
30 TLR-2, TLR-4, TLR-6, TLR-7, and TLR-8. Additionally, CpG has been reported to act through TLR 9.

In certain cells of the immune system, TLR activation can be associated with activation of the transcription factor NF- κ B. NF- κ B activation is associated with certain cellular responses to an immunological challenge, such as the production and secretion of pro-inflammatory cytokines such as TNF- α , IL-1, IL-6, IL-8, IL-10, IL-12, MIP-1, and MCP-1. IRM induction of such cellular responses can be demonstrated by measuring activation of the transcription factor NF- κ B in response to exposing a cell to an IRM compound (See, e.g., Chuang *et al.*, *Journ. of Leuk. Biol.*, vol. 71, pp. 538-544 (2002), and Hemmi *et al.*, *Nature Immunology*, vol. 3(2), pp. 196-200 (2002)). Thus, NF- κ B activation can be used as a reporter of TLR activation. However, the extent of NF- κ B activation does not necessarily correlate with the extent of the downstream cellular response. This is so because the downstream cellular response may be modulated by one or more additional factors.

Summary of the Invention

The present invention provides an expression system that includes a first nucleic acid sequence that encodes a Toll-like receptor operably linked to a first expression control sequence; and a second nucleic acid sequence that encodes a reporter that (a) generates a detectable signal when the reporter is expressed and the cell is exposed to conditions effective for generating the detectable signal, and (b) is operably linked to a second expression control sequence that comprises a cytokine promoter, a chemokine promoter, a co-stimulatory marker promoter, or a defensin promoter. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are included on a single vector. In other embodiments, the first nucleic acid sequence and the second nucleic acid sequence are located on separate vectors.

In another aspect, the present invention provides a recombinant cell line that includes a host cell transfected with an expression system. In some embodiments, the expression system is contained within a single vector. In other embodiments, the expression system is contained among two or more vectors so that the host cell is co-transfected with all of the vectors of the expression system to obtain the recombinant cell line. In one embodiment, the host cell is a Namalwa cell.

In another aspect, the present invention provides a TLR agonist identified using either an expression system or a recombinant cell line according to the present invention.

In yet another aspect, the present invention provides pharmaceutical compositions including a TLR agonist identified using either an expression system or a recombinant cell line according to the present invention.

5 Various other features and advantages of the present invention should become readily apparent with reference to the following detailed description, examples, and appended claims. In several places throughout the specification, guidance is provided through lists of examples. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list.

10 **Detailed Description of Illustrative Embodiments of the Invention**

The present invention provides gene expression systems and recombinant cell lines that may be useful for detecting TLR activation based on detecting induction of a downstream cellular response to TLR activation (e.g., production or secretion of one or more immune system compounds such as cytokines or co-stimulatory markers) rather than
15 NF- κ B activation. In some cases, the cellular response may be mediated by NF- κ B, but in other cases the cellular response may be NF- κ B-independent. Thus, the present invention provides gene expression systems and recombinant cell lines that may be useful for detecting a broader range of TLR activation than is possible by monitoring NF- κ B activation. This may provide an ability to identify certain TLR agonists that would not be
20 detected using an assay based on NF- κ B activation. The gene expression systems and recombinant cell lines of the present invention also may provide a more relevant indication of the quantitative character of a particular cellular response to TLR activation by a particular TLR agonist.

In some cases, a gene expression system or recombinant cell line according to the
25 present invention may be useful for detecting TLR activation that is not accompanied by NF- κ B activation. Accordingly, the gene expression system and recombinant cell line may be employed to identify TLR agonists that do not necessarily also activate NF- κ B. Such TLR agonists may be useful for treatment or prevention of certain conditions in which the production and secretion of pro-inflammatory cytokines such as those induced
30 by NF- κ B activation may be undesirable.

For purposes of this invention, the following terms shall have the meanings set forth.

“Activation” refers to modifying the indicated protein so that the protein provides a biological function. For example, TLR activation refers to modifying a TLR - for example, a conformational modification such as in response to exposure of the TLR to an agonist - so that the TLR is capable of inducing the production and secretion of certain cytokines.

“Agonist” refers to a compound that can combine with a receptor (e.g., a TLR) to produce a cellular response. An agonist may be a ligand that directly binds to the receptor. Alternatively, an agonist may combine with a receptor indirectly by, e.g., (a) forming a complex with another molecule that directly binds to the receptor, or (b) otherwise results in the modification of another compound so that the other compound directly binds to the receptor. An agonist may be referred to as an agonist of a particular TLR (e.g., a TLR6 agonist).

“Amino acid sequence” refers to a particular ordered sequence of amino acids, whether naturally occurring or engineered.

“Co-transfect” and variations thereof refer to transfecting a host cell with more than one vector. A host cell may be co-transfected by transfecting with two or more vectors one at a time or in any convenient combination of vectors, including simultaneous transfection with all vectors.

“Express” and variations thereof refer to the ability of a cell to transcribe a structural gene to mRNA, then translate the mRNA to synthesize a protein that provides a detectable biological or biochemical function. “Expressible” refers to the ability of a particular nucleic acid sequence to be expressed by a cell that contains the nucleic acid sequence.

“Immune system compound” refers to any compound that is produced or secreted by cells of the immune system in response to an immunological challenge. Immune system compounds include but are not limited to cytokines, chemokines, co-stimulatory markers, and defensins.

“IRM compound” refers to a compound that alters the level of one or more immune system compounds when administered to an IRM-responsive cell. Representative IRM compounds include the small organic molecules, purine derivatives, small heterocyclic compounds, amide derivatives, and oligonucleotide sequences described above.

“Nucleic acid sequence” refers generally to a region of DNA that has a definable function such as (a) encoding a peptide, polypeptide, or protein or (b) controlling expression of a nucleic acid sequence that encodes a peptide, polypeptide, or protein. For example, a nucleic acid sequence that encodes TLR6 refers generically to any sequence of nucleotides that encodes a TLR6 protein, without regard to (a) the species source of the nucleic acid sequence, (b) specific nucleotide sequence variants, or (c) whether such nucleotide sequence variants are naturally occurring or engineered.

“Nucleotide sequence” refers to a particular ordered sequence of nucleotide bases, whether naturally occurring or engineered.

It has been found that induction of certain secreted proteins or polypeptides can be useful as reporters of TLR activation. For example, IFN- α is a cytokine secreted by such immune system cells as T lymphocytes, macrophages, plasmacytoid monocytes, dendritic cells, and natural killer cells. IFN- α is involved in regulating a host's innate and adaptive immune responses to an immunological challenge, perhaps by providing a link between the two responses [Brassard *et al.*, *Journal of Leukocyte Biology* 71: 565-581 (2002)]. The innate immune response can include the cell-mediated response of natural killer (NK) cells to a non-self (e.g., neoplastic) or foreign (e.g., viral) antigen. IFN- α also may indirectly regulate the balance between Th1 and Th2 cell populations and, therefore, the innate and adaptive immune responses. Moreover, induction of IFN- α is independent of NF- κ B activation.

Additionally, the production and secretion of NF- κ B-dependent cytokines can be useful as reporters of cellular responses resulting from immunological challenge. Detection and measurement of such cytokines may provide comparative qualitative data regarding a cell's response to immunological challenge that is more relevant to an investigator than NF- κ B activation data.

Thus, in certain embodiments, the present invention relates to recombinant cell lines and gene expression systems designed to assist detecting induction of immune system compounds and identification of compounds that induce expression of immune system compounds through TLRs.

Parts of the following description are provided in the context of IFN- α induction and detection. However, many of the features of the embodiments described below also may be realized using expression systems and recombinant cell lines designed to

specifically detect or induce other immune system compounds. Thus, expression systems and recombinant cell lines designed to specifically detect or induce immune system compounds other than IFN- α are explicitly included in the scope of the present invention.

5 The present invention provides a recombinant cell line capable of inducing gene expression from an expression control sequence of a gene that encodes an immune system compound (e.g., IFN- α) in response to TLR activation. In some embodiments, for example, cells of the recombinant cell line, when exposed to a TLR agonist, can induce expression from an IFN- α promoter to a greater extent than cells of the corresponding untransfected cell line. Cells of the untransfected cell lines may substantially lack a
10 functional level of TLR expression (i.e., untransfected cells may not detectably induce expression from the IFN- α promoter in response to exposure to a TLR agonist). Alternatively, cells of the untransfected cell line may exhibit a baseline level of background TLR function, but the baseline level is less than the level of TLR function observed in cells of the corresponding recombinant (i.e., transfected) cell line.

15 Cells of the recombinant cell lines include a first nucleic acid sequence that encodes a TLR operably linked to an expression control sequence. The cells also include a second nucleic acid sequence that encodes a reporter capable of generating a detectable signal when it is expressed in the recombinant cell under conditions suitable for generating the detectable signal. The reporter is linked to a second expression control sequence that
20 is capable of being induced by activation of the TLR encoded by the first nucleic acid sequence.

The TLR encoded by the first nucleic acid sequence may be any TLR. Ten different human TLRs have been identified, cloned, and sequenced. TLRs also are known to exist in other mammals including, for example, mice and chimpanzees. The nucleotide
25 sequences of the ten human TLRs and many non-human TLRs are known, have been published, and are readily accessible from various sequence databases including GenBank. The first nucleic acid sequence may include the nucleotide sequence of any one of the TLRs, whether human or non-human. In one embodiment, the TLR is human TLR6; in another embodiment, the TLR is human TLR7. Alternatively, the first nucleic acid may
30 encode any one of the ten human TLRs, any non-human TLR, or any combination of two or more TLRs that may be desirable for a particular construct.

The first nucleic acid sequence can include a nucleotide sequence that differs from a specific published nucleotide sequence for the TLR encoded by the first nucleic acid sequence. For example, the first nucleic acid sequence can contain one or more substitutions (compared to a published TLR nucleotide sequence) that do not alter the amino acid sequence of the TLR protein expressed from the first nucleic acid sequence. Such a substitution may be termed a degenerate substitution. Nucleotide sequences containing one or more degenerate substitutions compared to a known TLR nucleotide sequence are explicitly included within the scope of nucleotide sequences suitable for use within the first nucleic acid sequence.

As another example, certain nucleotide substitutions may alter the amino acid sequence of the TLR protein. For certain amino acid substitutions, however, the chemical properties of the protein having the altered amino acid sequence are similar to the chemical properties of the protein having the native amino acid sequence. Amino acids may be divided into four groups based on the chemical characteristics of the amino acid side groups: neutral, non-polar amino acids include glycine, alanine, valine, isoleucine, leucine, phenylalanine, proline, and methionine; neutral, polar amino acids include serine, threonine, tyrosine, tryptophan, asparagine, glutamine, and cysteine; acidic amino acids include aspartic acid and glutamic acid; and basic amino acids include lysine, arginine, and histidine. Substitution of one amino acid for another amino acid within the same group may have little or no functional effect on the resulting protein because of the similarity of the chemical characteristics of the amino acids involved in the substitution. Such amino acid substitutions may be termed a conservative amino acid substitution. Nucleotide sequences that, when compared to a known TLR nucleotide sequence, generate one or more conservative amino acid substitutions are explicitly included within the scope of nucleotide sequences suitable for use within the first nucleic acid sequence.

The nucleic acid that encodes a TLR may be cloned into an expression vector so that it is under the expression control of its own promoter, a homologous TLR promoter, or any heterologous promoter inducible in an appropriate host cell. For example, in certain embodiments, the TLR6 structural gene may be cloned into the commercially available mammalian expression vector pCI-neo. In this case, the TLR6 structural gene may be cloned into the vector's cloning region using the *NheI* and *MluI* restrictions sites. In such an embodiment, after transfection of the vector into a mammalian cell, the TLR6

structural gene is under the transcriptional control of the vector's CMV enhancer/promoter region.

The second nucleic acid sequence encodes a reporter that is capable of generating a detectable signal when expressed in a host cell under conditions appropriate for generating the desired detectable signal. A wide variety of suitable reporter systems are known. For example, luciferase gene expression may generate a detectable luminescent signal under appropriate conditions. As another example, β -galactosidase expression can generate a detectable color change under appropriate conditions. As yet another example, production and secretion of an immune system compound may be detected by an enzyme-linked immunosorbent assay (ELISA). These and other reporter systems are known and assays for generating the detectable signals are commercially available.

The second nucleic acid sequence is operably linked to a second expression control sequence that includes a promoter sequence selected to be inducible by activation of the TLR encoded by the first nucleic acid sequence. Thus, expression and activation of the TLR encoded by the first nucleic acid sequence will induce gene expression from the second expression control sequence, thereby causing expression of the reporter, which may be detected by performing an assay designed to detect expression of the reporter. The second expression control sequence may include any suitable nucleotide sequence that can induce expression (e.g., a promoter) of a structural gene upon activation of the TLR encoded by the first nucleic acid sequence. Nucleotide sequences suitable for use as second expression control sequences include promoter sequences of TLR-inducible genes including but not limited to genes encoding cytokines, chemokines, co-stimulatory markers, and defensins. In certain embodiments, the second expression control sequence can include an IFN- α 1 promoter. When the reporter system being employed to detect TLR activation includes detecting production and secretion of an immune system compound with an appropriate ELISA assay, the second expression control sequence may include the promoter of the gene encoding the immune system compounds being expressed and detected as the reporter. However, in certain embodiments, it may be desirable to express the immune system compound from a heterologous promoter.

The first nucleic acid sequence and the second nucleic acid sequence may be contained within a single vector. Alternatively, the first nucleic acid sequence and the second nucleic acid sequence may be on separate vectors and co-transfected into a suitable

host cell. In certain embodiments, for example, the first nucleic acid sequence may be cloned into the pCI-neo vector as described above, while the second nucleic acid sequence can be cloned into a reporter vector. One example of a commercially available reporter vector is the pGL3-Enhancer vector, which includes a luciferase reporter gene downstream of a cloning site for cloning a promoter sequence of interest. In some embodiments, the promoter of a TLR-inducible immune system compound may be cloned into the pGL3-Enhancer cloning site. In one such embodiment, the IFN- α promoter may be cloned into the pGL3-Enhancer cloning site.

Suitable host cells include any transfectable cells capable of expressing exogenous mammalian genes. In some embodiments, the host cells may be mammalian cells such as human cells or mouse cells. For example, suitable host cells include human cells or descendants of a human cell including but not limited to Namalwa cells or HEK293 cells. Alternatively, the host cells may be mouse cells or descendants of a mouse cell including but not limited to RAW 264.7 cells.

In one embodiment, the host cells include Namalwa cells. Namalwa cells have certain characteristics that may be particularly desirable for certain embodiments of the present invention. For example, Namalwa cells can include an expressible chromosomal IFN- α gene locus. Thus, upon appropriate stimulation (e.g., viral infection), Namalwa cells can be induced to produce and secrete IFN- α from the chromosomal IFN- α gene locus. However, Namalwa cells do not naturally express certain TLRs (e.g., TLR6, TLR7, or TLR9). Certain agonists of such TLRs have been shown to induce IFN- α expression in other cell types (e.g., PMBCs), but may not induce IFN- α expression in Namalwa cells unless a functional level of TLR expression is provided.

Namalwa cells transfected with an expression system according to the present invention may be capable of expressing a functional level of the TLR provided by the expression system. Thus, Namalwa cells transfected with an expression system according to certain embodiments of the present invention may inducibly express IFN- α as a result of activating the cloned TLR (e.g., by exposure of the transfected Namalwa cells to an agonist). Thus, certain transfected cell lines of the present invention provide an ability to detect a TLR agonist by detecting TLR-mediated IFN- α expression by Namalwa cells. Such IFN- α expression may occur from the chromosomal IFN- α gene or from an IFN- α promoter cloned into the reporter vector.

Namalwa cells transfected with an expression system according to certain embodiments of the present invention can provide alternative means of detecting TLR expression. First, transfected Namalwa cells may generate a detectable signal as a result of expressing the reporter from the second expression control sequence, which may or
5 may not include an IFN- α promoter (see Table 2). Second, transfected Namalwa cells may produce and secrete IFN- α from the chromosomal IFN- α gene locus. A transfected Namalwa cell line according to the present invention may be used to screen compounds in order to identify those compounds that induce TLR expression, i.e., TLR agonists.

Therefore, the present invention also provides TLR agonist compounds identified
10 using an expression system or a recombinant cell line according to certain embodiments of the present invention. As described above, the expression systems and recombinant cell lines may provide the ability to identify TLR activation that may not be detectable using previously known TLR activation assays. A compound that induces TLR activity detectable by using a gene expression system or a recombinant cell line according to the
15 present invention may be considered a TLR agonist. Such TLR agonists may include chemical structures similar in certain respects to the chemical structures of known IRM compounds. Alternatively, a gene expression system or a recombinant cell line according to the present invention may provide a tool for the screening (e.g., high throughput screening) chemically diverse compounds that may lead to the discovery of new TLR
20 agonists, some of which may contain new chemical core structures capable of activating TLRs.

The present invention also provides pharmaceutical compositions containing a TLR agonist identified using an expression system or a recombinant cell line according to the present invention, or a pharmaceutically acceptable salt thereof, in an amount effective
25 for inducing a TLR-mediated cellular response.

Examples

The following examples have been selected merely to further illustrate features, advantages, and other details of the invention. It is to be expressly understood, however,
30 that while the examples serve this purpose, the particular materials and amounts used as well as other conditions and details are not to be construed in a matter that would unduly limit the scope of this invention.

Construction of vectors

The vector pIFN- α 1-luc was constructed by inserting BglII sites at both ends of the human IFN- α 1 promoter (SEQ ID NO:21). The BglII sites were inserted into the IFN- α 1 promoter and the sequence was amplified using the primer pair of SEQ ID NO:22 and SEQ ID NO:23. The amplified IFN- α 1 promoter was cloned into the pGL3-Enhancing vector (Promega Corp., Madison, WI) at its BglII site.

The vector pCI-TLR6 was constructed by inserting SEQ ID NO:11 (GenBank Accession No. NM 006068), which includes the human TLR6 coding sequence, into the pCI-neo mammalian expression vector (Promega Corp.) at the vector's NheI and MluI restriction sites.

Transfections

Unless otherwise indicated, all incubations were performed at 37°C with 5% CO₂ at 98% humidity.

Culture medium was prepared from complete RPMI 1640 medium (BioSource International, Inc., Camarillo, CA). Fetal bovine serum (Atlas Biologicals, Inc., Ft. Collins, CO) was added to a final concentration of 7.5% (vol/vol); L-glutamine (BioSource International, Inc.) was added to 5 mM; and sodium pyruvate (BioSource International, Inc.) was added to 1 mM.

Burkitt's Lymphoma lymphoblastoid Namalwa cells (ATCC Accession No. CRL-1432) were grown by incubation in culture medium overnight. Cells were harvested by centrifugation in a tabletop centrifuge (1200 RPM for 5 minutes), and then resuspended in phosphate buffered sucrose to a concentration of 1.3×10^7 cells per milliliter.

For each transfection, a 750 μ L aliquot of the cell suspension was placed in an electroporation cuvette with 4 mm gaps. 10 μ g of the pIFN- α 1-luc vector and 10 μ g of the pCI-TLR6 vector were added to the electroporation cuvette. The cell and vector mixtures were incubated at room temperature for 5 minutes. The cells were electroporated using a BioRad Gene Pulser (BioRad Laboratories, Hercules, CA) set to at 500 μ F capacitance and 0.27 volts, then incubated at room temperature for 5 minutes.

The electroporated cells were suspended in 10 mLs of culture medium and incubated overnight. Dead cells and debris were removed after 24 hours using a MACS

Dead Cell Removal kit (Miltenyi Biotec, Auburn, CA). Cells were resuspended in 10 mLs of culture medium and incubated for an additional 24 hours.

Transfected cells were selected by adding G418 (Promega Corp., Madison, WI) to a final concentration of 1 mg/mL and incubating the cells for seven days.

5

Assays

The selected transfected cells were counted and resuspended to a concentration of 1×10^6 cell per mL in culture medium. 100 μ L aliquots of cells were placed in the wells of a white-walled, white-bottomed 96-well plate (Corning, Inc. Corning, NY). 1.0 μ L of an IRM compound from Table 1 (prepared at 1 mM in 100% DMSO) was added to some cell aliquots so that the final concentration of IRM compound was 10 μ M. As a positive control, some cell aliquots were incubated with Sendai virus instead of IRM compound. As a negative control, some cell aliquots were incubated with DMSO without IRM compound. In all cases, the cells were incubated for 18 hours.

15

Table 1 - IRM Compounds

Compound	Chemical Name	Citation
IRM 1	4-amino-2-ethoxymethyl- α,α -dimethyl-6,7,8,9-tetrahydro-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinoline-1-ethanol	U.S. 5,352,784 Example 91
IRM 2	4-amino- $\alpha,\alpha,2$ -trimethyl-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinoline-1-ethanol	U.S. 5,266,575 Example C1
IRM 3	N-[4-(4-amino-2-butyl-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-1-yl)butyl]methanesulfonamide	U.S. 6,331,539 Example 6
IRM 4	1-{2-[3-(3-pyridyl)propoxy]ethyl}-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-4-amine	WO 02/46193 Example 33
IRM 5	2-butyl-1-(2-methylpropyl)-1 <i>H</i> -imidazo[4,5- <i>c</i>][1,5]naphthyridin-4-amine	U.S. 6,194,425 Example 39
IRM 6	2-butyl-6,7,8,9-tetrahydro-1-(2-methylpropyl)-1 <i>H</i> -imidazo[4,5- <i>c</i>][1,5]naphthyridin-4-amine	U.S. 6,194,425 Example 40
IRM 7	N ³ -{4-[4-amino-2-(2-methoxyethyl)-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-1-yl]butyl}-6-(1 <i>H</i> -1-pyrrolyl)nicotinamide	U.S. 6,451,810 Example 60
IRM 8	2-ethyl-1-[5-(methylsulfonyl)pentyl]-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-4-amine	WO 02/46192 Example 13

The plates were equilibrated to room temperature before 1 volume of reconstituted LucLight Plus (Packard Instruments, Meriden, CT) was added to each aliquot of cells. Each well of the plate was read on an LJI Analyst (LJI Biosystems, Inc., Sunnyvale, CA) set with a 5 minute dark adapt. Data from a representative experiment are shown in Table 2. The data are expressed as the fold increase in luciferase induction off of the IFN- α 1 promoter in cell aliquots incubated with the indicated stimulant compared to the negative control in which the cell aliquots were incubated with only DMSO.

Table 2 - TLR Expression by pIFN- α 1-luc/pCI-TLR6 Co-Transfected Namalwa cells

<u>Stimulant</u>	<u>Fold Increase in Luciferase Induction</u>
IRM1	3.6
IRM2	2.7
IRM3	2.6
IRM4	4.0
IRM5	3.2
IRM6	2.9
IRM7	3.2
IRM8	2.3
Sendai virus	2.7

The complete disclosures of the patents, patent documents and publications cited herein are incorporated by reference in their entirety as if each were individually incorporated. In case of conflict, the present specification, including definitions, shall control.

Various modifications and alterations to this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention. Illustrative embodiments and examples are provided as examples only and are not intended to limit the scope of the present invention. The scope of the invention is limited only by the claims set forth as follows.

What is Claimed is:

1. An expression system comprising:
a first nucleic acid sequence that encodes a Toll-like receptor operably linked to a first expression control sequence; and
5 a second nucleic acid sequence that encodes a reporter that (a) generates a detectable signal when the reporter is expressed and the cell is exposed to conditions effective for generating the detectable signal, and (b) is operably linked to a second expression control sequence that comprises a cytokine promoter, a chemokine promoter, a co-stimulatory marker promoter, or a defensin promoter.
10
2. The expression system of claim 1 wherein the second expression control sequence comprises an IFN- α promoter.
3. The expression system of claim 1 wherein the first nucleic acid sequence
15 comprises the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, or a degenerate variant of any of the foregoing.
4. The expression system of claim 1 wherein the first nucleic acid sequence
20 comprises a nucleotide sequence that encodes a polypeptide having the sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, or any one of the foregoing sequences with one or more conservative amino acid substitutions.
- 25 5. The expression system of claim 1 wherein the detectable signal comprises luciferase activity or β -galactosidase activity.
6. The expression system of claim 1 wherein a first vector comprises the first nucleic acid sequence and a second vector comprises the second nucleic acid sequence.
30
7. A vector comprising the expression system of claim 1.

8. A TLR agonist identified using the expression system of claim 1.
9. A pharmaceutical composition comprising the TLR agonist of claim 8, or a pharmaceutically acceptable salt thereof.
- 5 10. A cultured cell comprising the expression system of claim 1.
11. The cultured cell of claim 10 wherein the cell is a mammalian cell or a descendent of a mammalian cell.
- 10 12. The culture cell of claim 11 wherein the cell is a human cell or a descendent of a human cell.
13. The cultured cell of claim 10 further comprising an expressible nucleic acid sequence that encodes IFN- α operably linked to a third expression control sequence.
- 15 14. The cultured cell of claim 13 wherein the expressible nucleic acid sequence that encodes IFN- α is located on a chromosome of the cultured cell.
- 20 15. The cultured cell of claim 14 wherein the cultured cell is a Namalwa cell.
16. The cultured cell of claim 13 wherein the expressible nucleic acid sequence that encodes IFN- α is located on an extrachromosomal vector.
- 25 17. A TLR agonist identified using the cultured cell of claim 10.
18. A pharmaceutical composition comprising the TLR agonist of claim 17, or a pharmaceutically acceptable salt thereof.

30

58182US002.ST25.txt
SEQUENCE LISTING

<110> Gupta, Shalley K.
Ghosh, Tarun K.
Fink, Jason R.

<120> Gene Expression Systems and Recombinant Cell Lines

<130> 58182WO003

<160> 23

<170> PatentIn version 3.1

<210> 1

<211> 2832

<212> DNA

<213> Homo sapiens

<400> 1
acagactgcc aaatggaaca gacaagcagg ttgtcttgtg ttaaagaaaa tgagatatga 60
gtcagttact cccggaggca atgctgctgt tcagctcttg tgtttttgtg gccagggctt 120
tcatgaacac taataggggt accaggccct cttccttgtt agaagaaatc aggataacaa 180
aggtatattg ggcaccccta caaaaggaat ctgtatctgt atcaagatga tctgaagaac 240
agcttctacc tttaggaatg tctagtgttc caaaatgact agcatcttcc attttgcctat 300
tatcttcatg ttaatacttc agatcagaat acaattatct gaagaaagtg aatttttagt 360
tgatagggtca aaaaacgggtc tcatccacgt tcctaaagac ctatcccaga aaacaacaat 420
cttaaataata tcgcaaaatt atatatctga gctttggact tctgacatct tatcactgtc 480
aaaactgagg attttgataa tttctcataa tagaatccag tatcttgata tcagtgtttt 540
caaattcaac caggaattgg aatacttgga ttgtgccac aacaagttgg tgaagatttc 600
ttgccaccct actgtgaacc tcaagcactt ggacctgtca ttaatgcat ttgatgccct 660
gcctatatgc aaagagtttg gcaatatgtc tcaactaaaa tttctgggggt tgagcaccac 720
acacttagaa aaatctagtg tgctgccaat tgctcatttg aatatcagca aggtcttgct 780
ggctcttagga gagacttatg gggaaaaaga agaccctgag ggccttcaag actttaacac 840
tgagagtctg cacattgtgt tccccacaaa caaagaattc cattttatct tgatgtgtc 900
agtcaagact gtagcaaatac tggaactatc taatatcaaa tgtgtgctag aagataacaa 960
atgttcttac ttcctaagta ttctggcgaa acttcaaaca aatccaaagt tatcaagtct 1020
taccttaaac aacattgaaa caacttgga ttctttcatt aggatcctcc agctgggttg 1080
gcatacaact gtatggtatt tctcaatttc aaacgtgaag ctacaggggtc agctggactt 1140
cagagatttt gattattctg gcacttcctt gaaggccttg tctatacacc aagttgtcag 1200
cgatgtgttc gggtttccgc aaagttatat ctatgaaatc ttttcgaata tgaacatcaa 1260
aaatttcaca gtgtctggta cacgcatggt ccacatgctt tgcccatcca aaattagccc 1320

58182US002.ST25.txt

```

gttcctgcat ttggatTTTT ccaataatct cttaacagac acggTTTTtg aaaattgtgg 1380
gcaccttact gagttggaga cacttatTTT acaaatgaat caattaaaag aactttcaaa 1440
aatagctgaa atgactacac agatgaagtc tctgcaacaa ttggatatta gccagaattc 1500
tgtaagctat gatgaaaaga aaggagactg ttcttggact aaaagTTTat taagtttaaa 1560
tatgtcttca aatatactta ctgacactat tttcagatgt ttacctcca ggatcaaggT 1620
acttgatctt cacagcaata aaataaagag cattcctaaa caagtcgtaa aactggaagc 1680
tttgcaagaa ctcaatgttg ctttcaattc ttttaactgac cttcctggat gtggcagctt 1740
tagcagcctt tctgtattga tcattgatca caattcagtt tcccacccat cagctgattt 1800
cttcagagc tgccagaaga tgaggTcaat aaaagcaggg gacaatccat tccaatgtac 1860
ctgtgagcta ggagaatttg tcaaaaatat agaccaagta tcaagtgaag tgttagaggg 1920
ctggcctgat tcttataagt gtgactaccC ggaaagtTat agaggaaccC tactaaagga 1980
ctttcacatg tctgaattat cctgcaacat aactctgctg atcgTcacca tcgttgccac 2040
catgctggtg ttggctgtga ctgtgacctc cctctgcatc tacttggatc tgccctggta 2100
tctcaggatg gtgtgccagt ggaccCagac cgggcgcagg gccaggaaca tacccttaga 2160
agaactccaa agaaatctcc agtttcatgc atttatttca tatagtgggc acgattcttt 2220
ctgggtgaag aatgaattat tgccaaacct agagaaagaa ggtatgcaga tttgccttca 2280
tgagagaaac tttgttcctg gcaagagcat tgtggaaaat atcatcacct gcattgagaa 2340
gagttacaag tccatctttg ttttgtctcc caactttgtc cagagtgaat ggtgccatta 2400
tgaactctac tttgcccacC acaatctctt tcatgaagga tctaatagct taatcctgat 2460
cttgctggaa cccattccgc agtactccat tcctagcagt tatcacaagc tcaaaagtct 2520
catggccagg aggacttatt tggaatggcc caaggaaaag agcaaacgtg gcctTTTTtg 2580
ggctaactta agggcagcca ttaatatTaa gctgacagag caagcaaaga aatagattac 2640
acatcaagtg aaaaatattc ctctgttga tattgctgct tttggaagtT ccaacaatga 2700
ctttattttg catcagcata gatgtaaaca caattgtgag tgtatgatgt aggtaaaaat 2760
atataccttc gggtcgagT tcaccattta tatgtggTat taaaaattaa tgaaatgata 2820
taactttgat tt 2832

```

<210> 2
 <211> 786
 <212> PRT
 <213> Homo sapiens

<400> 2

Met Thr Ser Ile Phe His Phe Ala Ile Ile Phe Met Leu Ile Leu Gln
 1 5 10 15

58182US002.ST25.txt

Ile Arg Ile Gln Leu Ser Glu Glu Ser Glu Phe Leu Val Asp Arg Ser
 20 25 30
 Lys Asn Gly Leu Ile His Val Pro Lys Asp Leu Ser Gln Lys Thr Thr
 35 40 45
 Ile Leu Asn Ile Ser Gln Asn Tyr Ile Ser Glu Leu Trp Thr Ser Asp
 50 55 60
 Ile Leu Ser Leu Ser Lys Leu Arg Ile Leu Ile Ile Ser His Asn Arg
 65 70 75 80
 Ile Gln Tyr Leu Asp Ile Ser Val Phe Lys Phe Asn Gln Glu Leu Glu
 85 90 95
 Tyr Leu Asp Leu Ser His Asn Lys Leu Val Lys Ile Ser Cys His Pro
 100 105 110
 Thr Val Asn Leu Lys His Leu Asp Leu Ser Phe Asn Ala Phe Asp Ala
 115 120 125
 Leu Pro Ile Cys Lys Glu Phe Gly Asn Met Ser Gln Leu Lys Phe Leu
 130 135 140
 Gly Leu Ser Thr Thr His Leu Glu Lys Ser Ser Val Leu Pro Ile Ala
 145 150 155 160
 His Leu Asn Ile Ser Lys Val Leu Leu Val Leu Gly Glu Thr Tyr Gly
 165 170 175
 Glu Lys Glu Asp Pro Glu Gly Leu Gln Asp Phe Asn Thr Glu Ser Leu
 180 185 190
 His Ile Val Phe Pro Thr Asn Lys Glu Phe His Phe Ile Leu Asp Val
 195 200 205
 Ser Val Lys Thr Val Ala Asn Leu Glu Leu Ser Asn Ile Lys Cys Val
 210 215 220
 Leu Glu Asp Asn Lys Cys Ser Tyr Phe Leu Ser Ile Leu Ala Lys Leu
 225 230 235 240
 Gln Thr Asn Pro Lys Leu Ser Ser Leu Thr Leu Asn Asn Ile Glu Thr
 245 250 255
 Thr Trp Asn Ser Phe Ile Arg Ile Leu Gln Leu Val Trp His Thr Thr
 Page 3

58182US002.ST25.txt

260 265 270

Val Trp Tyr Phe Ser Ile Ser Asn Val Lys Leu Gln Gly Gln Leu Asp
 275 280 285

Phe Arg Asp Phe Asp Tyr Ser Gly Thr Ser Leu Lys Ala Leu Ser Ile
 290 295 300

His Gln Val Val Ser Asp Val Phe Gly Phe Pro Gln Ser Tyr Ile Tyr
 305 310 315 320

Glu Ile Phe Ser Asn Met Asn Ile Lys Asn Phe Thr Val Ser Gly Thr
 325 330 335

Arg Met Val His Met Leu Cys Pro Ser Lys Ile Ser Pro Phe Leu His
 340 345 350

Leu Asp Phe Ser Asn Asn Leu Leu Thr Asp Thr Val Phe Glu Asn Cys
 355 360 365

Gly His Leu Thr Glu Leu Glu Thr Leu Ile Leu Gln Met Asn Gln Leu
 370 375 380

Lys Glu Leu Ser Lys Ile Ala Glu Met Thr Thr Gln Met Lys Ser Leu
 385 390 395 400

Gln Gln Leu Asp Ile Ser Gln Asn Ser Val Ser Tyr Asp Glu Lys Lys
 405 410 415

Gly Asp Cys Ser Trp Thr Lys Ser Leu Leu Ser Leu Asn Met Ser Ser
 420 425 430

Asn Ile Leu Thr Asp Thr Ile Phe Arg Cys Leu Pro Pro Arg Ile Lys
 435 440 445

Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser Ile Pro Lys Gln Val
 450 455 460

Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val Ala Phe Asn Ser Leu
 465 470 475 480

Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser Leu Ser Val Leu Ile
 485 490 495

Ile Asp His Asn Ser Val Ser His Pro Ser Ala Asp Phe Phe Gln Ser
 500 505 510

58182US002.ST25.txt
 Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp Asn Pro Phe Gln Cys
 515 520 525

Thr Cys Glu Leu Gly Glu Phe Val Lys Asn Ile Asp Gln Val Ser Ser
 530 535 540

Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys Cys Asp Tyr Pro Glu
 545 550 555 560

Ser Tyr Arg Gly Thr Leu Leu Lys Asp Phe His Met Ser Glu Leu Ser
 565 570 575

Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Val Ala Thr Met Leu Val
 580 585 590

Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr Leu Asp Leu Pro Trp
 595 600 605

Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr Arg Arg Arg Ala Arg
 610 615 620

Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe
 625 630 635 640

Ile Ser Tyr Ser Gly His Asp Ser Phe Trp Val Lys Asn Glu Leu Leu
 645 650 655

Pro Asn Leu Glu Lys Glu Gly Met Gln Ile Cys Leu His Glu Arg Asn
 660 665 670

Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Thr Cys Ile Glu
 675 680 685

Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro Asn Phe Val Gln Ser
 690 695 700

Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His
 705 710 715 720

Glu Gly Ser Asn Ser Leu Ile Leu Ile Leu Leu Glu Pro Ile Pro Gln
 725 730 735

Tyr Ser Ile Pro Ser Ser Tyr His Lys Leu Lys Ser Leu Met Ala Arg
 740 745 750

Arg Thr Tyr Leu Glu Trp Pro Lys Glu Lys Ser Lys Arg Gly Leu Phe
 755 760 765

58182US002.ST25.txt

Trp Ala Asn Leu Arg Ala Ala Ile Asn Ile Lys Leu Thr Glu Gln Ala
 770 775 780

Lys Lys
 785

<210> 3
 <211> 2621
 <212> DNA
 <213> Homo sapiens

<400> 3
 cagtgtttgg tgttgcaagc aggatccaaa ggagacctat agtgactccc aggagctctt 60
 agtgaccaag tgaaggtagc tgtggggctc attgtgccc ttgctctttc actgctttca 120
 actggtagtt gtgggttgaa gcaactggaca atgccacata cttgtggat ggtgtgggtc 180
 ttgggggtca tcatcagcct ctccaaggaa gaatcctcca atcaggcttc tctgtcttgt 240
 gaccgcaatg gtatctgcaa gggcagctca ggatctttta actccattcc ctcagggttc 300
 acagaagctg taaaaagcct tgacctgtcc aacaacagga tcacctacat tagcaacagt 360
 gacctacaga ggtgtgtgaa cctccaggct ctggtgctga catccaatgg aattaacaca 420
 atagaggaag attctttttc ttccctgggc agtcttgaac atttagactt atcctataat 480
 tacttatcta atttatcgtc ttccctgggtc aagccccctt cttctttaac attcttaaac 540
 ttactgggaa atccttaca aaccctaggg gaaacatctc ttttttctca tctcacaaaa 600
 ttgcaaatcc tgagagtggg aaatatggac accttacta agattcaaag aaaagatttt 660
 gctggactta ctttccttga ggaacttgag attgatgctt cagatctaca gagctatgag 720
 ccaaaaagtt tgaagtcaat tcagaatgta agtcatctga tccttcatat gaagcagcat 780
 attttactgc tggagatttt tgtagatggt acaagttccg tggaatgttt ggaactgcga 840
 gatactgatt tggacacttt ccatttttca gaactatcca ctggtgaaac aaattcattg 900
 attaaaaagt ttacatttag aaatgtgaaa atcaccgatg aaagtttggt tcaggttatg 960
 aaacttttga atcagatttc tggattgtta gaattagagt ttgatgactg tacccttaat 1020
 ggagttggta atttttagag atctgataat gacagagtta tagatccagg taaagtggaa 1080
 acgttaacaa tccggaggct gcatattcca aggttttact tattttatga tctgagcact 1140
 ttatattcac ttacagaaag agttaaaaga atcacagtag aaaacagtaa agtttttctg 1200
 gttccttggt tactttcaca acatttaaaa tcattagaat acttgatct cagtgaaaat 1260
 ttgatgggtg aagaatactt gaaaaattca gcctgtgagg atgcctggcc ctctctacaa 1320
 actttaattt taaggcaaaa tcatttgga tcattggaaa aaaccggaga gactttgctc 1380
 actctgaaaa acttgactaa cattgatatc agtaagaata gttttcattc tatgcctgaa 1440

58182US002.ST25.txt

acttgtcagt ggccagaaaa gatgaaatat ttgaacttat ccagcacacg aatacacagt 1500
 gtaacaggct gcattcccaa gacactggaa attttagatg ttagcaacaa caatctcaat 1560
 ttattttctt tgaatttgcc gcaactcaaa gaactttata tttccagaaa taagttgatg 1620
 actctaccag atgcctccct cttacccatg ttactagtat tgaaaatcag taggaatgca 1680
 ataactacgt tttctaagga gcaacttgac tcatttcaca cactgaagac tttggaagct 1740
 ggtggcaata acttcatttg ctctgtgtaa ttctctctct tcactcagga gcagcaagca 1800
 ctggccaaag tcttgattga ttggccagca aattacctgt gtgactctcc atcccatgtg 1860
 cgtggccagc aggttcagga tgtccgcctc tcggtgtcgg aatgtcacag gacagcactg 1920
 gtgtctggca tgtgtgtgct tctgttcctg ctgacctctg tcacgggggt cctgtgccac 1980
 cgtttccatg gcctgtggta tatgaaaatg atgtgggcct ggctccaggc caaaaggaag 2040
 cccaggaag ctcccagcag gaacatctgc tatgatgcat ttgtttctta cagtgagcgg 2100
 gatgcctact ggggtggagaa ccttatggct caggagctgg agaacttcaa tcccccttc 2160
 aagttgtgtc ttcataagcg ggacttcatt cctggcaagt ggatcattga caatatcatt 2220
 gactccattg aaaagagcca caaaactgtc tttgtgcttt ctgaaaactt tgtgaagagt 2280
 gagtgggtga agtatgaact ggacttctcc catttcctgc tttttgatga gaacaatgat 2340
 gctgccattc tcattcttct ggagcccatt gagaaaaaag ccattcccca gcgcttctgc 2400
 aagctgcgga agataatgaa caccaagacc tacctggagt ggcccatgga cgaggctcag 2460
 cggaaggat tttgggtaaa tctgagagct gcgataaagt cctagggttc catatttaag 2520
 accagtcttt gtctagtgtg gatctttatg tcactagtta tagttaagtt cattcagaca 2580
 taattatata aaaactacgt ggatgtaccg tcatttgagg a 2621

<210> 4
 <211> 784
 <212> PRT
 <213> Homo sapiens

<400> 4

Met Pro His Thr Leu Trp Met Val Trp Val Leu Gly Val Ile Ile Ser
1 5 10 15

Leu Ser Lys Glu Glu Ser Ser Asn Gln Ala Ser Leu Ser Cys Asp Arg
20 25 30

Asn Gly Ile Cys Lys Gly Ser Ser Gly Ser Leu Asn Ser Ile Pro Ser
35 40 45

Gly Leu Thr Glu Ala Val Lys Ser Leu Asp Leu Ser Asn Asn Arg Ile
50 55 60

58182US002.ST25.txt

Thr Tyr Ile Ser Asn Ser Asp Leu Gln Arg Cys Val Asn Leu Gln Ala
 65 70 75 80
 Leu Val Leu Thr Ser Asn Gly Ile Asn Thr Ile Glu Glu Asp Ser Phe
 85 90 95
 Ser Ser Leu Gly Ser Leu Glu His Leu Asp Leu Ser Tyr Asn Tyr Leu
 100 105 110
 Ser Asn Leu Ser Ser Ser Trp Phe Lys Pro Leu Ser Ser Leu Thr Phe
 115 120 125
 Leu Asn Leu Leu Gly Asn Pro Tyr Lys Thr Leu Gly Glu Thr Ser Leu
 130 135 140
 Phe Ser His Leu Thr Lys Leu Gln Ile Leu Arg Val Gly Asn Met Asp
 145 150 155 160
 Thr Phe Thr Lys Ile Gln Arg Lys Asp Phe Ala Gly Leu Thr Phe Leu
 165 170 175
 Glu Glu Leu Glu Ile Asp Ala Ser Asp Leu Gln Ser Tyr Glu Pro Lys
 180 185 190
 Ser Leu Lys Ser Ile Gln Asn Val Ser His Leu Ile Leu His Met Lys
 195 200 205
 Gln His Ile Leu Leu Leu Glu Ile Phe Val Asp Val Thr Ser Ser Val
 210 215 220
 Glu Cys Leu Glu Leu Arg Asp Thr Asp Leu Asp Thr Phe His Phe Ser
 225 230 235 240
 Glu Leu Ser Thr Gly Glu Thr Asn Ser Leu Ile Lys Lys Phe Thr Phe
 245 250 255
 Arg Asn Val Lys Ile Thr Asp Glu Ser Leu Phe Gln Val Met Lys Leu
 260 265 270
 Leu Asn Gln Ile Ser Gly Leu Leu Glu Leu Glu Phe Asp Asp Cys Thr
 275 280 285
 Leu Asn Gly Val Gly Asn Phe Arg Ala Ser Asp Asn Asp Arg Val Ile
 290 295 300
 Asp Pro Gly Lys Val Glu Thr Leu Thr Ile Arg Arg Leu His Ile Pro
 305 310 315 320

58182US002.ST25.txt

Arg Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Leu Tyr Ser Leu Thr Glu
 325 330 335

Arg Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro
 340 345 350

Cys Leu Leu Ser Gln His Leu Lys Ser Leu Glu Tyr Leu Asp Leu Ser
 355 360 365

Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Glu Asp
 370 375 380

Ala Trp Pro Ser Leu Gln Thr Leu Ile Leu Arg Gln Asn His Leu Ala
 385 390 395 400

Ser Leu Glu Lys Thr Gly Glu Thr Leu Leu Thr Leu Lys Asn Leu Thr
 405 410 415

Asn Ile Asp Ile Ser Lys Asn Ser Phe His Ser Met Pro Glu Thr Cys
 420 425 430

Gln Trp Pro Glu Lys Met Lys Tyr Leu Asn Leu Ser Ser Thr Arg Ile
 435 440 445

His Ser Val Thr Gly Cys Ile Pro Lys Thr Leu Glu Ile Leu Asp Val
 450 455 460

Ser Asn Asn Asn Leu Asn Leu Phe Ser Leu Asn Leu Pro Gln Leu Lys
 465 470 475 480

Glu Leu Tyr Ile Ser Arg Asn Lys Leu Met Thr Leu Pro Asp Ala Ser
 485 490 495

Leu Leu Pro Met Leu Leu Val Leu Lys Ile Ser Arg Asn Ala Ile Thr
 500 505 510

Thr Phe Ser Lys Glu Gln Leu Asp Ser Phe His Thr Leu Lys Thr Leu
 515 520 525

Glu Ala Gly Gly Asn Asn Phe Ile Cys Ser Cys Glu Phe Leu Ser Phe
 530 535 540

Thr Gln Glu Gln Gln Ala Leu Ala Lys Val Leu Ile Asp Trp Pro Ala
 545 550 555 560

Asn Tyr Leu Cys Asp Ser Pro Ser His Val Arg Gly Gln Gln Val Gln
 Page 9

58182US002.ST25.txt
570

565

575

Asp Val Arg Leu Ser Val Ser Glu Cys His Arg Thr Ala Leu Val Ser
580 585 590

Gly Met Cys Cys Ala Leu Phe Leu Leu Ile Leu Leu Thr Gly Val Leu
595 600 605

Cys His Arg Phe His Gly Leu Trp Tyr Met Lys Met Met Trp Ala Trp
610 615 620

Leu Gln Ala Lys Arg Lys Pro Arg Lys Ala Pro Ser Arg Asn Ile Cys
625 630 635 640

Tyr Asp Ala Phe Val Ser Tyr Ser Glu Arg Asp Ala Tyr Trp Val Glu
645 650 655

Asn Leu Met Val Gln Glu Leu Glu Asn Phe Asn Pro Pro Phe Lys Leu
660 665 670

Cys Leu His Lys Arg Asp Phe Ile Pro Gly Lys Trp Ile Ile Asp Asn
675 680 685

Ile Ile Asp Ser Ile Glu Lys Ser His Lys Thr Val Phe Val Leu Ser
690 695 700

Glu Asn Phe Val Lys Ser Glu Trp Cys Lys Tyr Glu Leu Asp Phe Ser
705 710 715 720

His Phe Arg Leu Phe Asp Glu Asn Asn Asp Ala Ala Ile Leu Ile Leu
725 730 735

Leu Glu Pro Ile Glu Lys Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu
740 745 750

Arg Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Met Asp Glu
755 760 765

Ala Gln Arg Glu Gly Phe Trp Val Asn Leu Arg Ala Ala Ile Lys Ser
770 775 780

<210> 5
<211> 3057
<212> DNA
<213> Homo sapiens

<400> 5
cactttcgag agtgccgtct atttgccaca cacttcctg atgaaatgtc tggatttgga 60

58182US002.ST25.txt

ctaaagaaaa aaggaaaggc tagcagtcac	ccaacagaat catgagacag actttgcctt	120
gtatctactt ttgggggggc cttttgccct	ttgggatgct gtgtgcatcc tccaccacca	180
agtgcactgt tagccatgaa gttgctgact	gcagccacct gaagttgact caggtacccg	240
atgatctacc cacaaacata acagtgttga	accttaccca taatcaactc agaagattac	300
cagccgccaa cttcacaaagg tatagccagc	taactagctt ggatgtagga tttaacacca	360
tctcaaaact ggagccagaa ttgtgccaga	aacttcccat gttaaaagtt ttgaacctcc	420
agcacaatga gctatctcaa ctttctgata	aaacctttgc cttctgcacg aatttgactg	480
aactccatct catgtccaac tcaatccaga	aaattaaaaa taatcccttt gtcaagcaga	540
agaatttaat cacattagat ctgtctcata	atggcttgct atctacaaaa ttaggaactc	600
aggttcagct ggaaaatctc caagagcttc	tattatcaaa caataaaatt caagcgctaa	660
aaagtgaaga actggatatc tttgccaat	catctttaaa aaaattagag ttgtcatcga	720
atcaaattaa agagttttct ccagggtgtt	ttcacgcaat tggaagatta tttggcctct	780
ttctgaacaa tgtccagctg ggtcccagcc	ttacagagaa gctatgtttg gaattagcaa	840
acacaagcat tcggaatctg tctctgagta	acagccagct gtccaccacc agcaatacaa	900
ctttcttggg actaaagtgg acaaattctca	ctatgctcga tctttcctac aacaacttaa	960
atgtggttgg taacgattcc tttgcttggc	ttccacaact agaataatttc ttcctagagt	1020
ataataatat acagcatttg ttttctcact	ctttgcacgg gcttttcaat gtgagggtacc	1080
tgaatttgaa acggtctttt actaaacaaa	gtatttcctt tgcctcactc cccaagattg	1140
atgatttttc ttttcagtgg ctaaaatggt	tgagacacct taacatggaa gataatgata	1200
ttccaggcat aaaaagcaat atgttcacag	gattgataaa cctgaaatac ttaagtctat	1260
ccaactcctt tacaagtttg cgaactttga	caaatgaaac atttgatatca cttgctcatt	1320
ctcccttaca catactcaac ctaaccaaga	ataaaatctc aaaaatagag agtgatgctt	1380
tctcttgggt gggccaccta gaagtacttg	acctgggcct taatgaaatt gggcaagaac	1440
tcacaggcca ggaatggaga ggtctagaaa	atattttcga aatctatctt tcctacaaca	1500
agtacctgca gctgactagg aactcctttg	ccttgggtccc aagccttcaa cgactgatgc	1560
tccgaagggt ggcccttaaa aatgtggata	gctctccttc accattccag cctcttcgta	1620
acttgaccat tctggatcta agcaacaaca	acatagccaa cataaatgat gacatgttgg	1680
agggtcttga gaaactagaa attctcgatt	tgacagcataa caacttagca cggctctgga	1740
aacacgcaaa ccctgggtgt cccatttatt	tcctaaaggg tctgtctcac ctccacatcc	1800
ttaacttggg gtccaacggc tttgacgaga	tccagttga ggtcttcaag gatttatttg	1860
aactaaagat catcgattta ggattgaata	atttaaacac acttccagca tctgtcttta	1920
ataatcaggt gtctctaaag tcattgaacc	ttcagaagaa tctcataaca tccgttgaga	1980

58182US002.ST25.txt

```

agaaggtttt cgggccagct ttcaggaacc tgactgagtt agatatgcgc tttaatccct 2040
ttgattgcac gtgtgaaagt attgcctggt ttgttaattg gattaacgag acccatacca 2100
acatccctga gctgtcaagc cactaccttt gcaacactcc acctcactat catgggttcc 2160
cagtgagact ttttgataca tcattcttga aagacagtgc cccctttgaa ctctttttca 2220
tgatcaatac cagtatcctg ttgattttta tctttattgt acttctcatc cactttgagg 2280
gctggaggat atctttttat tggaatgttt cagtacatcg agttcttggg ttcaaagaaa 2340
tagacagaca gacagaacag tttgaatatg cagcatatat aattcatgcc tataaagata 2400
aggattgggt ctgggaacat ttctcttcaa tggaaaagga agaccaatct ctcaaatttt 2460
gtctggaaga aagggaacttt gaggcgggtg tttttgaact agaagcaatt gttaacagca 2520
tcaaaagaag cagaaaaatt atttttgtta taacacacca tctattaaaa gaccattat 2580
gcaaaagatt caaggtacat catgcagttc aacaagctat tgaacaaaat ctggattcca 2640
ttatatgggt tttccttgag gagattccag attataaact gaaccatgca ctctgtttgc 2700
gaagaggaat gtttaaatct cactgcatct tgaactggcc agttcagaaa gaacggatag 2760
gtgccttttc tcataaattg caagtagcac ttggatccaa aaactctgta cattaaattt 2820
atttaaatat tcaattagca aaggagaaac tttctcaatt taaaaagttc tatggcaaat 2880
ttaagttttc cataaagggt ttataatttg tttattcata tttgtaaattg attatattct 2940
atcacaatta catctcttct aggaaaatgt gtctccttat ttcaggccta tttttgacaa 3000
ttgacttaat ttaccctaaa ataaaacata taagcacgta aaaaaaaaaa aaaaaaa 3057

```

<210> 6
 <211> 904
 <212> PRT
 <213> Homo sapiens

<400> 6

Met Arg Gln Thr Leu Pro Cys Ile Tyr Phe Trp Gly Gly Leu Leu Pro
 1 5 10 15

Phe Gly Met Leu Cys Ala Ser Ser Thr Thr Lys Cys Thr Val Ser His
 20 25 30

Glu Val Ala Asp Cys Ser His Leu Lys Leu Thr Gln Val Pro Asp Asp
 35 40 45

Leu Pro Thr Asn Ile Thr Val Leu Asn Leu Thr His Asn Gln Leu Arg
 50 55 60

Arg Leu Pro Ala Ala Asn Phe Thr Arg Tyr Ser Gln Leu Thr Ser Leu
 65 70 75 80

Asp	Val	Gly	Phe	Asn 85	Thr	Ile	Ser	Lys	Leu 90	Glu	Pro	Glu	Leu	Cys 95	Gln
Lys	Leu	Pro	Met 100	Leu	Lys	Val	Leu	Asn 105	Leu	Gln	His	Asn	Glu 110	Leu	Ser
Gln	Leu	Ser 115	Asp	Lys	Thr	Phe	Ala 120	Phe	Cys	Thr	Asn	Leu 125	Thr	Glu	Leu
His	Leu 130	Met	Ser	Asn	Ser	Ile 135	Gln	Lys	Ile	Lys	Asn 140	Asn	Pro	Phe	Val
Lys 145	Gln	Lys	Asn	Leu	Ile 150	Thr	Leu	Asp	Leu	Ser 155	His	Asn	Gly	Leu	Ser 160
Ser	Thr	Lys	Leu	Gly 165	Thr	Gln	Val	Gln	Leu 170	Glu	Asn	Leu	Gln	Glu 175	Leu
Leu	Leu	Ser	Asn 180	Asn	Lys	Ile	Gln	Ala 185	Leu	Lys	Ser	Glu	Glu 190	Leu	Asp
Ile	Phe	Ala 195	Asn	Ser	Ser	Leu	Lys 200	Lys	Leu	Glu	Leu	Ser 205	Ser	Asn	Gln
Ile	Lys 210	Glu	Phe	Ser	Pro	Gly 215	Cys	Phe	His	Ala	Ile 220	Gly	Arg	Leu	Phe
Gly 225	Leu	Phe	Leu	Asn	Asn 230	Val	Gln	Leu	Gly	Pro 235	Ser	Leu	Thr	Glu	Lys 240
Leu	Cys	Leu	Glu	Leu 245	Ala	Asn	Thr	Ser	Ile 250	Arg	Asn	Leu	Ser	Leu 255	Ser
Asn	Ser	Gln	Leu 260	Ser	Thr	Thr	Ser	Asn 265	Thr	Thr	Phe	Leu	Gly 270	Leu	Lys
Trp	Thr	Asn 275	Leu	Thr	Met	Leu	Asp 280	Leu	Ser	Tyr	Asn	Asn 285	Leu	Asn	Val
Val	Gly 290	Asn	Asp	Ser	Phe	Ala 295	Trp	Leu	Pro	Gln	Leu 300	Glu	Tyr	Phe	Phe
Leu 305	Glu	Tyr	Asn	Asn	Ile 310	Gln	His	Leu	Phe	Ser 315	His	Ser	Leu	His	Gly 320
Leu	Phe	Asn	Val	Arg	Tyr	Leu	Asn	Leu	Lys	Arg	Ser	Phe	Thr	Lys	Gln

58182US002.ST25.txt
330

325

335

Ser Ile Ser Leu Ala Ser Leu Pro Lys Ile Asp Asp Phe Ser Phe Gln
340 345 350

Trp Leu Lys Cys Leu Glu His Leu Asn Met Glu Asp Asn Asp Ile Pro
355 360 365

Gly Ile Lys Ser Asn Met Phe Thr Gly Leu Ile Asn Leu Lys Tyr Leu
370 375 380

Ser Leu Ser Asn Ser Phe Thr Ser Leu Arg Thr Leu Thr Asn Glu Thr
385 390 395 400

Phe Val Ser Leu Ala His Ser Pro Leu His Ile Leu Asn Leu Thr Lys
405 410 415

Asn Lys Ile Ser Lys Ile Glu Ser Asp Ala Phe Ser Trp Leu Gly His
420 425 430

Leu Glu Val Leu Asp Leu Gly Leu Asn Glu Ile Gly Gln Glu Leu Thr
435 440 445

Gly Gln Glu Trp Arg Gly Leu Glu Asn Ile Phe Glu Ile Tyr Leu Ser
450 455 460

Tyr Asn Lys Tyr Leu Gln Leu Thr Arg Asn Ser Phe Ala Leu Val Pro
465 470 475 480

Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val Asp
485 490 495

Ser Ser Pro Ser Pro Phe Gln Pro Leu Arg Asn Leu Thr Ile Leu Asp
500 505 510

Leu Ser Asn Asn Asn Ile Ala Asn Ile Asn Asp Asp Met Leu Glu Gly
515 520 525

Leu Glu Lys Leu Glu Ile Leu Asp Leu Gln His Asn Asn Leu Ala Arg
530 535 540

Leu Trp Lys His Ala Asn Pro Gly Gly Pro Ile Tyr Phe Leu Lys Gly
545 550 555 560

Leu Ser His Leu His Ile Leu Asn Leu Glu Ser Asn Gly Phe Asp Glu
565 570 575

58182US002.ST25.txt

Ile Pro Val Glu Val Phe Lys Asp Leu Phe Glu Leu Lys Ile Ile Asp
580 585 590

Leu Gly Leu Asn Asn Leu Asn Thr Leu Pro Ala Ser Val Phe Asn Asn
595 600 605

Gln Val Ser Leu Lys Ser Leu Asn Leu Gln Lys Asn Leu Ile Thr Ser
610 615 620

Val Glu Lys Lys Val Phe Gly Pro Ala Phe Arg Asn Leu Thr Glu Leu
625 630 635 640

Asp Met Arg Phe Asn Pro Phe Asp Cys Thr Cys Glu Ser Ile Ala Trp
645 650 655

Phe Val Asn Trp Ile Asn Glu Thr His Thr Asn Ile Pro Glu Leu Ser
660 665 670

Ser His Tyr Leu Cys Asn Thr Pro Pro His Tyr His Gly Phe Pro Val
675 680 685

Arg Leu Phe Asp Thr Ser Ser Cys Lys Asp Ser Ala Pro Phe Glu Leu
690 695 700

Phe Phe Met Ile Asn Thr Ser Ile Leu Leu Ile Phe Ile Phe Ile Val
705 710 715 720

Leu Leu Ile His Phe Glu Gly Trp Arg Ile Ser Phe Tyr Trp Asn Val
725 730 735

Ser Val His Arg Val Leu Gly Phe Lys Glu Ile Asp Arg Gln Thr Glu
740 745 750

Gln Phe Glu Tyr Ala Ala Tyr Ile Ile His Ala Tyr Lys Asp Lys Asp
755 760 765

Trp Val Trp Glu His Phe Ser Ser Met Glu Lys Glu Asp Gln Ser Leu
770 775 780

Lys Phe Cys Leu Glu Glu Arg Asp Phe Glu Ala Gly Val Phe Glu Leu
785 790 795 800

Glu Ala Ile Val Asn Ser Ile Lys Arg Ser Arg Lys Ile Ile Phe Val
805 810 815

Ile Thr His His Leu Leu Lys Asp Pro Leu Cys Lys Arg Phe Lys Val
820 825 830

58182US002.ST25.txt

His His Ala Val Gln Gln Ala Ile Glu Gln Asn Leu Asp Ser Ile Ile
 835 840 845

Leu Val Phe Leu Glu Glu Ile Pro Asp Tyr Lys Leu Asn His Ala Leu
 850 855 860

Cys Leu Arg Arg Gly Met Phe Lys Ser His Cys Ile Leu Asn Trp Pro
 865 870 875 880

Val Gln Lys Glu Arg Ile Gly Ala Phe Arg His Lys Leu Gln Val Ala
 885 890 895

Leu Gly Ser Lys Asn Ser Val His
 900

<210> 7
 <211> 3811
 <212> DNA
 <213> Homo sapiens

<400> 7
 acagggccac tgctgctcac agaagcagtg aggatgatgc caggatgatg tctgcctcgc 60
 gcctggctgg gactctgac ccagccatgg ccttcctctc ctgcgtgaga ccagaaagct 120
 gggagccctg cgtggagact tggccctaaa ccacacagaa gagctggcat gaaaccaga 180
 gctttcagac tccggagcct cagcccttca ccccgattcc attgcttctt gctaaatgct 240
 gccgttttat cacggaggtg gttcctaata ttacttatca atgcatggag ctgaatttct 300
 acaaaatccc cgacaacctc cccttctcaa ccaagaacct ggacctgagc tttaatcccc 360
 tgaggcattt aggcagctat agcttcttca gtttccaga actgcagggtg ctggatttat 420
 ccagggtgtga aatccagaca attgaagatg gggcatatca gaggcctaagc cacctctcta 480
 ccttaatat gacaggaaac cccatccaga gtttagccct gggagccttt tctggactat 540
 caagtttaca gaagctggtg gctgtggaga caaatctagc atctctagag aacttcccc 600
 ttggacatct caaaactttg aaagaactta atgtggctca caatcttatc caatctttca 660
 aattacctga gtatTTTTT aatctgacca atctagagca cttggacctt tccagcaaca 720
 agattcaaag tatttattgc acagacttgc gggttctaca tcaaagtccc ctactcaatc 780
 tctctttaga cctgtccctg aaccctatga actttatcca accaggtgca tttaaagaaa 840
 ttaggcttca taagctgact ttaagaaata attttgatag tttaaatgta atgaaaactt 900
 gtattcaagg tctggctggt ttagaagtc atcgtttgggt tctgggagaa tttagaaatg 960
 aaggaaactt ggaaaagttt gacaaatctg ctctagaggg cctgtgcaat ttgaccattg 1020
 aagaattccg attagcatat ttagactact acctcgatga tattattgac ttatttaatt 1080

58182US002.ST25.txt

gtttgacaaa tgtttcttca ttttccctgg tgagtgtgac tattgaaagg gtaaaagact 1140
 tttcttataa tttcggatgg caacatttag aattagttaa ctgtaaattt ggacagtttc 1200
 ccacattgaa actcaaatct ctcaaaaggc ttactttcac ttccaacaaa ggtgggaatg 1260
 ctttttcaga agttgatcta ccaagccttg agttttctaga tctcagtaga aatggccttga 1320
 gtttcaaagg ttgctgttct caaagtgatt ttgggacaac cagcctaaag tatttagatc 1380
 tgagcttcaa tgggtgttatt accatgagtt caaacttctt gggccttagaa caactagaac 1440
 atctggattt ccagcattcc aatttgaaac aaatgagtga gttttcagta ttcctatcac 1500
 tcagaaacct cattttacctt gacattttctc atactcacac cagagttgct ttcaatggca 1560
 tcttcaatgg cttgtccagt ctcgaagtct tgaaaatggc tggcaattct ttccaggaaa 1620
 acttccttcc agatatcttc acagagctga gaaacttgac cttcctggac ctctctcagt 1680
 gtcaactgga gcagttgtct ccaacagcat ttaactcact ctccagtctt caggtactaa 1740
 atatgagcca caacaacttc ttttcattgg atacgtttcc ttataagtgt ctgaactccc 1800
 tccaggttct tgattacagt ctcaatcaca taatgacttc caaaaaacag gaactacagc 1860
 attttccaag tagtctagct ttcttaaadc ttactcagaa tgactttgct tgtacttggtg 1920
 aacaccagag tttcctgcaa tggatcaagg accagaggca gctcttggtg gaagttgaac 1980
 gaatggaatg tgcaacacct tcagataagc agggcatgcc tgtgctgagt ttgaatatca 2040
 cctgtcagat gaataagacc atcattgggtg tgtcggtcct cagtgtgctt gtagtatctg 2100
 ttgtagcagt tctggtctat aagttctatt ttcacctgat gcttcttgct ggctgcataa 2160
 agtatggtag aggtgaaaac atctatgatg cttttgttat ctactcaagc caggatgagg 2220
 actgggtaag gaatgagcta gtaaagaatt tagaagaagg ggtgcctcca tttcagctct 2280
 gccttcacta cagagacttt attcccgggtg tggccattgc tgccaacatc atccatgaag 2340
 gtttcataa aagccgaaag gtgattgttg tgggtgccca gcacttcac cagagccgct 2400
 ggtgtatctt tgaatatgag attgctcaga cctggcagtt tctgagcagt cgtgctggta 2460
 tcatcttcat tgtcctgcag aaggtggaga agaccctgct caggcagcag gtggagctgt 2520
 accgccttct cagcaggaac acttacctgg agtgggagga cagtgtcctg gggcggcaca 2580
 tcttctggag acgactcaga aaagccctgc tggatggtaa atcatggaat ccagaaggaa 2640
 cagtgggtac aggatgcaat tggcaggaag caacatctat ctgaagagga aaaataaaaa 2700
 cctcctgagg catttcttgc ccagctgggt ccaacacttg ttcagttaat aagtattaaa 2760
 tgctgccaca tgtcaggcct tatgctaagg gtgagtaatt ccatgggtgca ctagatatgc 2820
 agggctgcta atctcaagga gcttccagtg cagaggggaat aaatgctaga ctaaaataca 2880
 gagtcttcca ggtgggcatt tcaaccaact cagtcaagga acccatgaca aagaaagtca 2940
 tttcaactct tacctcatca agttgaataa agacagagaa aacagaaaga gacattgttc 3000

58182US002.ST25.txt

```

ttttcctgag tcttttgaat ggaaattgta ttatgttata gccatcataa aaccattttg 3060
gtagttttga ctgaactggg tgttcacttt ttcctttttg attgaataca atttaaattc 3120
tacttgatga ctgcagtcgt caaggggctc ctgatgcaag atgccccttc cattttaagt 3180
ctgtctcctt acagagggtta aagtctaattg gctaattcct aaggaaacct gattaacaca 3240
tgctcacaac catcctgggtc attctcgaac atgttctatt ttttaactaa tcaccctga 3300
tatattttta tttttatata tccagttttc atttttttac gtcttgcccta taagctaata 3360
tcataaataa gggtgtttta gacgtgcttc aaatatccat attaaccact atttttcaag 3420
gaagtatgga aaagtacact ctgtcacttt gtcactcgat gtcattccaa agttattgcc 3480
tactaagtaa tgactgtcat gaaagcagca ttgaaataat ttgtttaaag ggggcactct 3540
tttaaacggg aagaaaattt ccgcttcctg gtcttatcat ggacaatttg ggctataggg 3600
atgaaggaag tgggattacc tcaggaagtc accttttctt gattccagaa acatatgggc 3660
tgataaaccc ggggtgacct catgaaatga gttgcagcag atgtttatit ttttcagaac 3720
aagtgatgtt tgatggacct atgaatctat ttagggagac acagatggct gggatccctc 3780
ccctgtaccc ttctcactga caggagaact a 3811

```

<210> 8
 <211> 799
 <212> PRT
 <213> Homo sapiens

<400> 8

Met Glu Leu Asn Phe Tyr Lys Ile Pro Asp Asn Leu Pro Phe Ser Thr
 1 5 10 15

Lys Asn Leu Asp Leu Ser Phe Asn Pro Leu Arg His Leu Gly Ser Tyr
 20 25 30

Ser Phe Phe Ser Phe Pro Glu Leu Gln Val Leu Asp Leu Ser Arg Cys
 35 40 45

Glu Ile Gln Thr Ile Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu
 50 55 60

Ser Thr Leu Ile Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly
 65 70 75 80

Ala Phe Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr
 85 90 95

Asn Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu
 100 105 110

58182US002.ST25.txt

Lys Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro
 115 120 125

Glu Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser
 130 135 140

Asn Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln
 145 150 155 160

Met Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn
 165 170 175

Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr
 180 185 190

Leu Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln
 195 200 205

Gly Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg
 210 215 220

Asn Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu
 225 230 235 240

Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr
 245 250 255

Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser
 260 265 270

Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr
 275 280 285

Asn Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln
 290 295 300

Phe Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser
 305 310 315 320

Asn Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu
 325 330 335

Phe Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser
 340 345 350

Gln Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe
 Page 19

Page 20

58182US002.ST25.txt

Val Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys
 610 615 620

Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr
 625 630 635 640

Ser Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu
 645 650 655

Glu Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe
 660 665 670

Ile Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His
 675 680 685

Lys Ser Arg Lys Val Ile Val Val Val Ser Gln His Phe Ile Gln Ser
 690 695 700

Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu
 705 710 715 720

Ser Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys
 725 730 735

Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn
 740 745 750

Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp
 755 760 765

Arg Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu
 770 775 780

Gly Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile
 785 790 795

<210> 9
 <211> 1261
 <212> DNA
 <213> Homo sapiens

<400> 9
 tgttgggatg tttttgaggg actttctcat cttcaagttc tgtatttgaa tcataactat 60
 cttaattccc ttccaccagg agtatttagc catctgactg cattaagggg actaagcctc 120
 aactccaaca ggctgacagt tctttctcac aatgatttac ctgctaattt agagatcctg 180
 gacatatcca ggaaccagct cctagctcct aatcctgatg tatttgatc acttagtgtc 240
 ttggatataa ctcataacaa gttcatttgt gaatgtgaac ttagcacttt tatcaattgg 300

58182US002.ST25.txt

```

cttaatcaca ccaatgtcac tatagctggg cctcctgcag acatatattg tgtgtaccct 360
gactcgttct ctgggggtttc cctcttctct cttccacgg aaggttgtga tgaagaggaa 420
gtcttaaagt ccctaaagtt ctcccttttc attgtatgca ctgtcactct gactctgttc 480
ctcatgacca tcctcacagt cacaaagttc cggggcttct gttttatctg ttataagaca 540
gccagagac tgggtgttcaa ggaccatccc cagggcacag aacctgatat gtacaaatat 600
gatgcctatt tgtgcttcag cagcaaagac ttcacatggg tgcagaatgc tttgctcaaa 660
cacctggaca ctcaatacag tgacacaaac agattcaacc tgtgctttga agaaagagac 720
tttgctccag gagaaaaccg cattgccaat atccaggatg ccatctggaa cagtagaaag 780
atcgtttgtc ttgtgagcag acacttcctt agagatggct ggtgccttga agccttcagt 840
tatgccagg gcaggtgctt atctgacctt aacagtgtc tcatcatggt ggtggttggg 900
tccttgctcc agtaccagtt gatgaaacat caatccatca gaggctttgt acagaaacag 960
cagtatttga ggtggcctga ggatctccag gatgttggct ggtttcttca taaactctct 1020
caacagatac taaagaaaga aaaagaaaag aagaaagaca ataacattcc gttgcaaact 1080
gtagcaacca tctcctaadc aaaggagcaa tttccaactt atctcaagcc acaaataact 1140
cttcactttg tatttgcacc aagttatcat tttggggtcc tctctggagg tttttttttt 1200
ctttttgcta ctatgaaaac aacataaatc tctcaatttt cgtatcaaaa aaaaaaaaaa 1260
a 1261

```

<210> 10
 <211> 204
 <212> PRT
 <213> Homo sapiens

<400> 10

Met Thr Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys
 1 5 10 15

Tyr Lys Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly Thr
 20 25 30

Glu Pro Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser Lys
 35 40 45

Asp Phe Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr Gln
 50 55 60

Tyr Ser Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp Phe
 65 70 75 80

58182US002.ST25.txt

Val Pro Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp Asn
85 90 95

Ser Arg Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp Gly
100 105 110

Trp Cys Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp
115 120 125

Leu Asn Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln Tyr
130 135 140

Gln Leu Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln Gln
145 150 155 160

Tyr Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His
165 170 175

Lys Leu Ser Gln Gln Ile Leu Lys Lys Glu Lys Glu Lys Lys Lys Asp
180 185 190

Asn Asn Ile Pro Leu Gln Thr Val Ala Thr Ile Ser
195 200

<210> 11
<211> 2753
<212> DNA
<213> Homo sapiens

<400> 11
agaatttggg ctcatatcaa gatgctctga agaagaacaa cccttttagga tagccactgc 60
aacatcatga ccaaagacaa agaacctatt gttaaagct tccattttgt ttgccttatg 120
atcataatag ttggaaccag aatccagttc tccgacggaa atgaatttgc agtagacaag 180
tcaaaaagag gtcttattca tgttccaaaa gacctaccgc tgaaaaccaa agtcttagat 240
atgtctcaga actacatcgc tgagcttcag gtctctgaca tgagctttct atcagagttg 300
acagttttga gactttccca taacagaatc cagctacttg atttaagtgt tttcaagttc 360
aaccaggatt tagaatattt ggatttatct cataatcagt tgcaaaagat atcctgccat 420
cctattgtga gtttcaggca tttagatctc tcattcaatg atttcaaggc cctgcccac 480
tgtaaggaat ttggcaactt atcacaactg aatttcttgg gattgagtgc tatgaagctg 540
caaaaattag atttgctgcc aattgctcac ttgcatctaa gttatatcct tctggattta 600
agaaattatt atataaaaga aaatgagaca gaaagtctac aaattctgaa tgcaaaaacc 660
cttcaccttg tttttcaccc aactagttta ttcgctatcc aagtgaacat atcagttaat 720
actttagggt gcttacaact gactaatatt aaattgaatg atgacaactg tcaagttttc 780

58182US002.ST25.txt

attaaatatt tatcagaact caccagaggt tcaaccttac tgaattttac cctcaaccac 840
atagaaacga cttggaaatg cctggtcaga gtctttcaat ttctttggcc caaacctgtg 900
gaatatctca atattttaca tttacaata attgaaagca ttcgtgaaga agattttact 960
tattctaaaa cgacattgaa agcattgaca atagaacata tcacgaacca agtttttctg 1020
ttttcacaga cagctttgta caccgtgttt tctgagatga acattatgat gtttaaccatt 1080
tcagatacac cttttataca catgctgtgt cctcatgcac caagcacatt caagtttttg 1140
aactttacc agaacgtttt cacagatagt atttttgaaa aatgttccac gttagttaaa 1200
ttggagacac ttatcttaca aaaaaatgga ttaaaagacc ttttcaaagt aggtctcatg 1260
acgaaggata tgccttcttt ggaaatactg gatgttagct ggaattcttt ggaatctggt 1320
agacataaag aaaactgcac ttgggttgag agtatagtgg tgttaaattt gtcttcaaatt 1380
atgcttactg actctgtttt cagatgttta cctcccagga tcaaggtact tgatcttcac 1440
agcaataaaa taaagagcgt tcctaacaa gtcgtaaac tggaagcttt gcaagaactc 1500
aatgttgctt tcaattcttt aactgacctt cctggatgtg gcagcttag cagcctttct 1560
gtattgatca ttgatcaca ttcatgttcc caccatcgg ctgatttctt ccagagctgc 1620
cagaagatga ggtcaataaa agcaggggac aatccattcc aatgtacctg tgagctaaga 1680
gaatttgta aaaatataga ccaagtatca agtgaagtgt tagagggtg gcctgattct 1740
tataagtgtg actaccaga aagttataga ggaagccac taaaggactt tcacatgtct 1800
gaattatcct gcaacataac tctgctgac gtcaccatcg gtgccaccat gctggtgttg 1860
gctgtgactg tgacctccct ctgcatctac ttggatctgc cctggtatct caggatggtg 1920
tgccagtga cccagactcg gcgcagggcc aggaacatac ccttagaaga actccaaaga 1980
aacctccagt ttcattgttt ttttcatat agtgaacatg attctgcctg ggtgaaaagt 2040
gaattggtac cttacctaga aaaagaagat atacagattt gtcttcatga gaggaacttt 2100
gtccctggca agagcattgt ggaaaatatc atcaactgca ttgagaagag ttacaagtcc 2160
atctttgttt tgtctcccaa ctttgtccag agtgagtggg gccattacga actctatattt 2220
gcccacaca atctctttca tgaaggatct aataacttaa tcctcatctt actggaacct 2280
attccacaga acagattcc caacaagtac cacaagctga aggtctcat gacgcagcgg 2340
acttatttgc agtggcccaa ggagaaaagc aaacgtgggc tcttttgggc taacattaga 2400
gccgctttta atatgaaatt aacactagtc actgaaaaca atgatgtgaa atcttaaaaa 2460
aatttaggaa attcaactta agaaaccatt atttacttgg atgatggtga atagtacagt 2520
cgtaagtaac tgtctggagg tgccctcatt atcctcatgc cttcaggaaa gacttaacaa 2580
aaacaatggt tcactgtggg aactgagcta ggcggtgagg ttagcctgcc agttagagac 2640

58182US002.ST25.txt

agcccagtcct cttctggttt aatcattatg tttcaaattg aaacagtcctc ttttgagtaa 2700
 atgctcagtt tttcagctcc tctccactct gctttcccaa atggattctg ttg 2753

<210> 12
 <211> 796
 <212> PRT
 <213> Homo sapiens
 <400> 12

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys
 1 5 10 15
 Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn
 20 25 30
 Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys
 35 40 45
 Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile
 50 55 60
 Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val
 65 70 75 80
 Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe
 85 90 95
 Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu
 100 105 110
 Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu
 115 120 125
 Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn
 130 135 140
 Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys
 145 150 155 160
 Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu
 165 170 175
 Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln
 180 185 190
 Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu
 195 200 205

58182US002.ST25.txt

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln
 210 215 220
 Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys
 225 230 235 240
 Phe Leu Ser Glu Leu Thr Arg Gly Ser Thr Leu Leu Asn Phe Thr Leu
 245 250 255
 Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe
 260 265 270
 Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile
 275 280 285
 Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu
 290 295 300
 Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser
 305 310 315 320
 Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu
 325 330 335
 Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro
 340 345 350
 Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser
 355 360 365
 Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu
 370 375 380
 Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys
 385 390 395 400
 Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu
 405 410 415
 Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val
 420 425 430
 Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu
 435 440 445
 Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser
 450 455 460

58182US002.ST25.txt

Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val
 465 470 475 480
 Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser
 485 490 495
 Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala
 500 505 510
 Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp
 515 520 525
 Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile
 530 535 540
 Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys
 545 550 555 560
 Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His
 565 570 575
 Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly
 580 585 590
 Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr
 595 600 605
 Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr
 610 615 620
 Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu
 625 630 635 640
 Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val
 645 650 655
 Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys
 660 665 670
 Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile
 675 680 685
 Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro
 690 695 700
 Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His
 Page 27

58182US002.ST25.txt
 705 710 715 720
 His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu
 725 730 735
 Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys
 740 745 750
 Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser
 755 760 765
 Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys
 770 775 780
 Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser
 785 790 795

<210> 13
 <211> 5007
 <212> DNA
 <213> Homo sapiens

<400> 13
 actccagata taggatcact ccatgccatc aagaaagttg atgctattgg gcccatctca 60
 agctgatctt ggcacctctc atgctctgct ctcttcaacc agacctctac attccatttt 120
 ggaagaagac taaaaatggt gtttccaatg tggacactga agagacaaat tcttatcctt 180
 tttaacataa tcctaatttc caaactcctt ggggctagat ggtttcctaa aactctgccc 240
 tgtgatgtca ctctggatgt tccaaagaac catgtgatcg tggactgcac agacaagcat 300
 ttgacagaaa ttcttgaggg tattcccacg aacaccacga acctcaccct caccattaac 360
 cacataccag acatctcccc agcgtccttt cacagactgg accatctggg agagatcgat 420
 ttcagatgca actgtgtacc tattccactg ggggtcaaaaa acaacatgtg catcaagagg 480
 ctgcagatta aaccagaag ctttagtgga ctcaattatt taaaatccct ttacctggat 540
 ggaaccagc tactagagat accgcagggc ctccgccta gcttacagct tctcagcctt 600
 gaggccaaca acatcttttc catcagaaaa gagaatctaa cagaactggc caacatagaa 660
 atactctacc tgggccaata ctgttattat cgaaatcctt gttatgtttc atattcaata 720
 gagaaagatg ctttcctaaa cttgacaaag ttaaaagtgc tctccctgaa agataacaat 780
 gtcacagccg tccctactgt ttgcatct actttaacag aactatatct ctacaacaac 840
 atgattgcaa aaatccaaga agatgatatt aataacctca accaattaca aattcttgac 900
 ctaagtggaa attgccctcg ttgttataat gccccatttc cttgtgcgcc gtgtaaaaat 960
 aattctcccc tacagatccc tgtaaagtgt tttgatgcgc tgacagaatt aaaagtttta 1020

58182US002.ST25.txt

cgtctacaca gtaactctct tcagcatgtg	cccccaagat ggtttaagaa catcaacaaa	1080
ctccaggaac tggatctgtc ccaaaacttc	ttggccaaag aaattgggga tgctaaattt	1140
ctgcattttc tccccagcct catccaattg	gatctgtctt tcaattttga acttcagggtc	1200
tatcgtgcat ctatgaatct atcacaagca	ttttcttcac tgaaaagcct gaaaattctg	1260
cggatcagag gatatgtctt taaagagttg	aaaagcttta acctctcgcc attacataat	1320
cttcaaaatc ttgaagttct tgatcttggc	actaacttta taaaaattgc taacctcagc	1380
atgtttaaac aatttaaaag actgaaagtc	atagatcttt cagtgaataa aatatcacct	1440
tcaggagatt caagtgaagt tggcttctgc	tcaaatgccg gaacttctgt agaaagtatt	1500
gaaccccagg tcctggaaca attacattat	ttcagatatg ataagtatgc aaggagttgc	1560
agattcaaaa acaaagaggc ttctttcatg	tctgttaatg aaagctgcta caagtatggg	1620
cagaccttgg atctaagtaa aaatagtata	ttttttgtca agtcctctga ttttcagcat	1680
ctttctttcc tcaaatgcct gaatctgtca	ggaaatctca ttagccaaac tcttaatggc	1740
agtgaattcc aacctttagc agagctgaga	tatttggact tctccaacaa ccggcttgat	1800
ttactccatt caacagcatt tgaagagctt	cacaaactgg aagttctgga tataagcagt	1860
aatagccatt attttcaatc agaaggaatt	actcatatgc taaactttac caagaaccta	1920
aaggttctgc agaaactgat gatgaacgac	aatgacatct cttcctccac cagcaggacc	1980
atggagagtg agtctcttag aactctggaa	ttcagaggaa atcacttaga tgttttatgg	2040
agagaaggtg ataacagata cttacaatta	ttcaagaatc tgctaaaatt agaggaatta	2100
gacatctcta aaaattccct aagtttcttg	ccttctggag tttttgatgg tatgcctcca	2160
aatctaaaga atctctcttt ggccaaaaat	gggctcaaat ctttcagttg gaagaaactc	2220
cagtgtctaa agaacttgga aactttggac	ctcagccaca accaactgac cactgtccct	2280
gagagattat ccaactgttc cagaagcctc	aagaatctga ttcttaagaa taatcaaatc	2340
aggagtctga cgaagtattt tctacaagat	gccttccagt tgcgatatct ggatctcagc	2400
tcaaataaaa tccagatgat ccaaaagacc	agcttcccag aaaatgtcct caacaatctg	2460
aagatgttgc ttttgcacat taatcgggtt	ctgtgcacct gtgatgctgt gtgggttgtc	2520
tggtggttga accatacggg ggtgactatt	ccttacctgg ccacagatgt gacttgtgtg	2580
gggccaggag cacacaaggg ccaaagtgtg	atctccctgg atctgtacac ctgtgagtta	2640
gatctgacta acctgattct gttctcactt	tccatatctg tatctctctt tctcatgggtg	2700
atgatgacag caagtcacct ctatttctgg	gatgtgtggt atattttacca tttctgtaag	2760
gccaaagataa aggggtatca gcgtctaata	tcaccagact gttgctatga tgcttttatt	2820
gtgtatgaca ctaaagaccc agctgtgacc	gagtgggttt tggctgagct ggtggccaaa	2880
ctggaagacc caagagagaa acattttaat	ttatgtctcg aggaaagga ctggttacca	2940

58182US002.ST25.txt

gggcagccag ttctgaaaa cttttcccag agcatacagc ttagcaaaaa gacagtgttt 3000
gtgatgacag acaagtatgc aaagactgaa aattttaaga tagcatttta cttgtcccat 3060
cagaggctca tggatgaaaa agttgatgtg attatcttga tatttcttga gaagcccttt 3120
cagaagtcca agttcctcca gctccgaaaa aggctctgtg ggagtctgt ctttgagtgg 3180
ccaacaaacc cgcaagtca cccatacttc tggcagtgtc taaagaacgc cctggccaca 3240
gacaatcatg tggcctatag tcaggtgttc aaggaaacgg tctagccctt ctttgcaaaa 3300
cacaactgcc tagtttacca aggagaggcc tggctgttta aattgttttc atatatatca 3360
caccaaaagc gtgttttgaa attcttcaag aaatgagatt gcccatattt caggggagcc 3420
accaacgtct gtcacaggag ttggaaagat ggggtttata taatgcatca agtcttcttt 3480
cttatctctc tgtgtctcta tttgacttg agtctctcac ctcagctcct gtaaaagagt 3540
ggcaagtaaa aaacatgggg ctctgattct cctgtaattg tgataattaa atatacacac 3600
aatcatgaca ttgagaagaa ctgcatttct acccttaaaa agtactggta tatacagaaa 3660
taggggttaa aaaaactcaa gctctctcta tatgagacca aaatgtacta gagttagttt 3720
agtgaataaa aaaaccagtc agctggccgg gcatgggtggc tcatgcttgt aatcccagca 3780
ctttgggagg ccgaggcagg tggatcacga ggtcaggagt ttgagaccag tctggccaac 3840
atggtgaaac ccgctctgta ctaaaaatac aaaaattagc tgggcgtggg ggtgggtgcc 3900
tgtaatccca gctacttggg aggctgaggc aggagaatcg cttgaaccg ggaggtggag 3960
gtggcagtga gccgagatca cgccactgca atgcagccg ggcaacagag ctgactgtc 4020
tcaaaagaac aaaaaaaaaa aaacacaaaa aaactcagtc agcttcttaa ccaattgctt 4080
ccgtgtcatc cagggcccca ttctgtgcag attgagtgtg ggcaccacac aggtggttgc 4140
tgcttcagtg ctctctgctc ttttcccttg ggcctgcttc tgggttccat agggaaacag 4200
taagaaagaa agacacatcc ttaccataaa tgcatatggt ccacctaca atagaaaaat 4260
atttaaatga tctgccttta tacaaagtga tattctctac ctttgataat ttacctgctt 4320
aaatgttttt atctgcactg caaagtactg tatccaaagt aaaatttcct catccaatat 4380
ctttcaaact gttttgttaa ctaatgccat atatttgtaa gtatctgcac acttgataca 4440
gcaacgttag atggttttga tggtaaacc ctaaaggagga ctccaagagt gtgtatttat 4500
ttatagtttt atcagagatg acaattattt gaatgccaat tatatggatt ctttcat 4560
tttgctggag gatgggagaa gaaaccaaaag tttatagacc ttcacattga gaaagcttca 4620
gttttgaact tcagctatca gattcaaaaa caacagaaag aaccaagaca ttcttaagat 4680
gcctgtactt tcagctgggt ataaattcat gagttcaaag attgaaacct gaccaatttg 4740
ctttatttca tggaagaagt gatctacaaa ggtgtttgtg ccatttggaa aacagcgtgc 4800

58182US002.ST25.txt

atgtgttcaa gccttagatt ggcgatgtcg tattttcctc acgtgtggca atgccaaagg 4860
 ctttacttta cctgtgagta cacactatat gaattatttc caacgtacat ttaatcaata 4920
 agggtcacaa attcccaaatt caatctctgg aataaataga gaggttaatta aattgctgga 4980
 gccaaactatt tcacaacttc tgtaagc 5007

<210> 14
 <211> 1049
 <212> PRT
 <213> Homo sapiens

<400> 14

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe
 1 5 10 15

Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys
 20 25 30

Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile
 35 40 45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro
 50 55 60

Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile
 65 70 75 80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe
 85 90 95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys
 100 105 110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr
 115 120 125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln
 130 135 140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile
 145 150 155 160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile
 165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser
 180 185 190

58182US002.ST25.txt

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val
 195 200 205
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro
 210 215 220
 Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile
 225 230 235 240
 Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu
 245 250 255
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro
 260 265 270
 Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala
 275 280 285
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His
 290 295 300
 Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp
 305 310 315 320
 Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu
 325 330 335
 His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu
 340 345 350
 Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser
 355 360 365
 Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu
 370 375 380
 Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu
 385 390 395 400
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met
 405 410 415
 Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys
 420 425 430
 Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala
 435 440 445

58182US002.ST25.txt

Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His
 450 455 460
 Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys
 465 470 475 480
 Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln
 485 490 495
 Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp
 500 505 510
 Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu
 515 520 525
 Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu
 530 535 540
 Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr
 545 550 555 560
 Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn
 565 570 575
 Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr
 580 585 590
 Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile
 595 600 605
 Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu
 610 615 620
 Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn
 625 630 635 640
 Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp
 645 650 655
 Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly
 660 665 670
 Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys
 675 680 685
 Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu
 Page 33

Page 34

58182US002.ST25.txt

Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys
 945 950 955 960

Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln
 965 970 975

Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu
 980 985 990

Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys
 995 1000 1005

Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro
 1010 1015 1020

Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His
 1025 1030 1035

Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val
 1040 1045

<210> 15
 <211> 3311
 <212> DNA
 <213> Homo sapiens

<400> 15
 ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca acagaaacat ggaaaacatg 60
 ttctttcagt cgtcaatgct gacctgcatt ttcttgctaa tatctgggtc ctgtgagtta 120
 tgcgccgaag aaaatttttc tagaagctat ccttgatgat agaaaaagca aaatgactca 180
 gttattgcag agtgcagcaa tcgtcgacta caggaagttc cccaaacggt gggcaaatat 240
 gtgacagaac tagacctgtc tgataatttc atcacacaca taacgaatga atcatttcaa 300
 gggctgcaaa atctcactaa aataaatcta aaccacaacc ccaatgtaca gcaccagaac 360
 ggaaatcccg gtatacaatc aaatggcttg aatatcacag acggggcatt cctcaaccta 420
 aaaaacctaa gggagttact gcttgaagac aaccagttac cccaaatacc ctctgggttg 480
 ccagagtctt tgacagaact tagtctaatt caaaacaata tataacaat aactaaagag 540
 ggcatttcaa gacttataaa cttgaaaaat ctctatttgg cctggaactg ctattttaac 600
 aaagtttgcg agaaaactaa catagaagat ggagtatttg aaacgctgac aaatttggag 660
 ttgctatcac tatctttcaa ttctctttca cacgtgccac ccaaactgcc aagctcccta 720
 cgcaaacttt ttctgagcaa caccagatc aaatacatta gtgaagaaga tttcaagggg 780
 ttgataaatt taacattact agatttaagc gggaactgtc cgagggtgctt caatgcccc 840
 tttccatgcg tgccttgatga tgggtggtgct tcaattaata tagatcgttt tgcttttcaa 900

58182US002.ST25.txt

```

aacttgaccc aacttcgata cctaaacctc tctagcactt ccctcaggaa gattaatgct 960
gcctggttta aaaatatgcc tcatctgaag gtgctggatc ttgaattcaa ctatttagtg 1020
ggagaaatag cctctggggc atttttaacg atgctgcccc gcttagaaat acttgacttg 1080
tcttttaact atataaaggg gagttatcca cagcatatta atatttccag aaacttctct 1140
aaacttttgt ctctacgggc attgcattta agaggttatg tgttccagga actcagagaa 1200
gatgatttcc agcccctgat gcagcttcca aacttatcga ctatcaactt ggggtattaat 1260
tttattaagc aaatcgatth caaacttttc caaaatttct ccaatctgga aattatttac 1320
ttgtcagaaa acagaatatc accgttggtg aaagataccc ggcagagtta tgcaaatagt 1380
tcctcttttc aacgtcatat ccggaaacga cgctcaacag attttgagtt tgaccacat 1440
tcgaactttt atcatttcac ccgtccttta ataaagccac aatgtgctgc ttatggaaaa 1500
gccttagatt taagcctcaa cagtattttc ttcatggggc caaaccaatt tgaaaatctt 1560
cctgacattg cctgttttaa tctgtctgca aatagcaatg ctcaagtgtt aagtggaaact 1620
gaattttcag ccattcctca tgtcaaatat ttggatttga caaacaatag actagacttt 1680
gataatgcta gtgctcttac tgaattgtcc gacttggaag ttctagatct cagctataat 1740
tcacactatt tcagaatagc aggcgtaaca catcatctag aatttatcca aaatttcaca 1800
aatctaaaag ttttaaacct gagccacaac aacatttata cttaacaga taagtataac 1860
ctggaaagca agtccctggt agaattagtt ttcagtggca atcgcttga cttttgtgg 1920
aatgatgatg acaacaggta tatctccatt ttcaaaggct tcaagaatct gacacgtctg 1980
gatttatccc ttaataggct gaagcacatc ccaaatgaag cattccttaa tttgccagcg 2040
agtctcactg aactacatat aaatgataat atgttaaagt tttttaactg gacattactc 2100
cagcagttcc ctgctctcga gttgcttgac ttacgtggaa acaaactact ctttttaact 2160
gatagcctat ctgactttac atcttccctt cggacactgc tgctgagtca taacaggatt 2220
tcccacctac cctctggctt tctttctgaa gtcagtagtc tgaagcacct cgatttaagt 2280
tccaatctgc taaaaacaat caacaaatcc gcacttgaaa ctaagaccac caccaaatta 2340
tctatgttgg aactacacgg aaaccccttt gaatgcacct gtgacattgg agatttccga 2400
agatggatgg atgaacatct gaatgtcaaa attcccagac tggtagatgt cttttgtgcc 2460
agtcctgggg atcaaagagg gaagagtatt gtgagtctgg agctgacaac ttgtgtttca 2520
gatgtcactg cagtgatatt atttttcttc acgttcttta tcaccaccat gggtatgttg 2580
gctgccctgg ctaccatttt gttttactgg gatgtttggt ttatatataa tgtgtgttta 2640
gctaaggtaa aaggctacag gtctctttcc acatcccaa ctttctatga tgcttacatt 2700
tcttatgaca ccaaagatgc ctctgttact gactgggtga taaatgagct gcgctaccac 2760

```

58182US002.ST25.txt

```

cttgaagaga gccgagacaa aaacgttctc cttgtctag aggagagga ttgggacccg 2820
ggattggcca tcatcgacaa cctcatgcag agcatcaacc aaagcaagaa aacagtattt 2880
gtttaacca aaaaatatgc aaaaagctgg aactttaaaa cagcttttta cttggctttg 2940
cagaggctaa tggatgagaa catggatgtg attatattta tcctgctgga gccagtgtta 3000
cagcattctc agtatgtgag gctacggcag cggatctgta agagctccat cctccagtgg 3060
cctgacaacc cgaaggcaga aggcttgttt tggcaaaactc tgagaaatgt ggtcttgact 3120
gaaaatgatt cacggtataa caatatgtat gtcgattcca ttaagcaata ctaactgacg 3180
ttaagtcatg atttcgcgcc ataataaaga tgcaaaggaa tgacatttct gtattagtta 3240
tctattgcta tgtaacaaat tatcccaaaa cttagtgggt taaaacaaca catttgctgg 3300
cccacagttt t 3311

```

<210> 16
 <211> 1041
 <212> PRT
 <213> Homo sapiens

<400> 16

Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu
 1 5 10 15

Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg
 20 25 30

Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu
 35 40 45

Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr
 50 55 60

Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn
 65 70 75 80

Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His
 85 90 95

Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn
 100 105 110

Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg
 115 120 125

Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu
 130 135 140

58182US002.ST25.txt

Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn
 145 150 155 160
 Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr
 165 170 175
 Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile
 180 185 190
 Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu
 195 200 205
 Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu
 210 215 220
 Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu
 225 230 235 240
 Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn
 245 250 255
 Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly
 260 265 270
 Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln
 275 280 285
 Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala
 290 295 300
 Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe
 305 310 315 320
 Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu
 325 330 335
 Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser
 340 345 350
 Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser
 355 360 365
 Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu
 370 375 380
 Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn
 385 390 395 400

58182US002.ST25.txt

Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn
 405 410 415
 Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro
 420 425 430
 Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln
 435 440 445
 Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His
 450 455 460
 Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala
 465 470 475 480
 Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile
 485 490 495
 Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu Asn Leu
 500 505 510
 Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe Ser Ala
 515 520 525
 Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu Asp Phe
 530 535 540
 Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val Leu Asp
 545 550 555 560
 Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His
 565 570 575
 Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser
 580 585 590
 His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys
 595 600 605
 Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile Leu Trp
 610 615 620
 Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu Lys Asn
 625 630 635 640
 Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile Pro Asn
 Page 39

58182US002.ST25.txt
650

645

655

Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His Ile Asn
 660 665 670
 Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro
 675 680 685
 Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr
 690 695 700
 Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser
 705 710 715 720
 His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val Ser
 725 730 735
 Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr Ile Asn
 740 745 750
 Lys Ser Ala Leu Glu Thr Lys Thr Thr Thr Lys Leu Ser Met Leu Glu
 755 760 765
 Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp Phe Arg
 770 775 780
 Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu Val Asp
 785 790 795 800
 Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile Val Ser
 805 810 815
 Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile Leu Phe
 820 825 830
 Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala
 835 840 845
 His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu
 850 855 860
 Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr
 865 870 875 880
 Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp
 885 890 895

58182US002.ST25.txt

Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn
 900 905 910

Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile
 915 920 925

Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe
 930 935 940

Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe
 945 950 955 960

Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile
 965 970 975

Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu
 980 985 990

Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro
 995 1000 1005

Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu
 1010 1015 1020

Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile
 1025 1030 1035

Lys Gln Tyr
 1040

<210> 17
 <211> 3352
 <212> DNA
 <213> Homo sapiens

<400> 17
 aggctggtat aaaaatctta cttcctctat tctctgagcc gctgctgccc ctgtgggaag 60
 ggacctcgag tgtgaagcat cttccctgt agctgctgtc cagtctgccc gccagaccct 120
 ctggagaagc cctgcccc cagcatgggt ttctgccga ggcacctgca cccgctgtct 180
 ctcttggtgc aggccatcat gctggccatg accctggccc tgggtacctt gcctgccttc 240
 ctaccctgtg agctccagcc ccacggcctg gtgaactgca actggctgtt cctgaagtct 300
 gtgccccact tctccatggc agcaccctgt ggcaatgtca ccagccttc cttgtcctcc 360
 aaccgcatcc accacctcca tgattctgac ttgcccacc tgcccagcct gcggcatctc 420
 aacctcaagt ggaactgccc gccggttggc ctacgcccc tgcacttccc ctgccacatg 480
 accatcgagc ccagcacctt cttggctgtg cccaccctgg aagagctaaa cctgagctac 540

58182US002.ST25.txt

aacaacatca tgactgtgcc tgcgctgccc aaatccctca tatccctgtc cctcagccat	600
accaacatcc tgatgctaga ctctgccagc ctcgccggcc tgcattgccct gcgcttccta	660
ttcatggacg gcaactgtta ttacaagaac ccctgcaggc aggcactgga ggtggccccg	720
ggtgcccctcc ttggcctggg caacctcacc cacctgtcac tcaagtacaa caacctcact	780
gtgggtgcccc gcaacctgcc ttccagcctg gagtatctgc tgttgtccta caaccgcatc	840
gtcaaactgg cgcctgagga cctggccaat ctgaccgccc tgcgtgtgct cgatgtgggc	900
ggaaattgcc gccgctgcga ccacgtccc aaccctgca tggagtggc tcgtcacttc	960
ccccagctac atcccgatac cttcagccac ctgagccgtc ttgaaggcct ggtgttgaag	1020
gacagtcttc tctctgggt gaatgccagt tggttccgtg ggctgggaaa cctccgagt	1080
ctggacctga gtgagaactt cctctacaaa tgcattacta aaaccaaggc cttccagggc	1140
ctaacacagc tgcgcaagct taacctgtcc ttcaattacc aaaagagggt gtcctttgcc	1200
cacctgtctc tggccccctt cttcgggagc ctggctgccc tgaaggagct ggacatgcac	1260
ggcatcttct tccgtcact cgatgagacc acgctccggc cactggcccc cctgccccatg	1320
ctccagactc tgcgtctgca gatgaactt atcaaccagg cccagctcgg catcttcagg	1380
gccttccctg gcctgcgcta cgtggacctg tcggacaacc gcatcagcgg agcttcggag	1440
ctgacagcca ccatggggga ggcagatgga ggggagaagg tctggctgca gcctggggac	1500
cttgctccgg cccagtgga cactcccagc tctgaagact tcaggcccaa ctgcagcacc	1560
ctcaacttca ccttggatct gtcacggaac aacctgggtga ccgtgcagcc ggagatgttt	1620
gcccagctct cgacctgca gtgcctgctc ctgagccaca actgcatctc gcaggcagtc	1680
aatggctccc agttcttgc gctgaccggt ctgcagggtc tagacctgtc ccgaataag	1740
ctggacctct accacgagca ctcatcacg gagctaccgc gactggaggc cctggacctc	1800
agctacaaca gccagccctt tggcatgcag ggcgtgggccc acaacttcag cttcgtggct	1860
cacctgcgca ccctgcgcca cctcagcctg gcccacaaca acatccacag ccaagtgtcc	1920
cagcagctct gcagtacgtc gctgcggggc ctggacttca gcggcaatgc actgggcat	1980
atgtgggccc agggagacct ctatctgcac ttcttccaag gcctgagcgg tttgatctgg	2040
ctggacttgt cccagaaccg cctgcacacc ctctgcccc aaaccctgcg caacctcccc	2100
aagagcctac aggtgctgcg tctccgtgac aattacctgg cttcttttaa gtggtggagc	2160
ctccacttcc tgcccaact ggaagtcctc gacctggcag gaaaccggct gaaggccctg	2220
accaatggca gcctgcctgc tggcaccggt ctccggaggc tggatgtcag ctgcaacagc	2280
atcagcttgc tggcccccg cttcttttcc aaggccaagg agctgcgaga gctcaacctt	2340
agcgcacaac ccctcaagac agtggaccac tcctggtttg ggccccctggc gactgcccctg	2400

58182US002.ST25.txt

caaataactag atgtaagcgc caaccctctg cactgcgcct gtggggcggc ctttatggac 2460
 ttcttgctgg aggtgcaggc tgccgtgccc ggtctgccc gccgggtgaa gtgtggcagt 2520
 ccgggccagc tccagggcct cagcatcttt gcacaggacc tgcgcctctg cctggatgag 2580
 gccctctcct gggactgttt cgccctctcg ctgctggctg tggctctggg cctgggtgtg 2640
 cccatgctgc atcacctctg tggctgggac ctctgggtact gcttccacct gtgcctggcc 2700
 tggcttcctt ggcgggggcg gcaaagtggg cgagatgagg atgccctgcc ctacgatgcc 2760
 ttctgtgtct tcgacaaaac gcagagcgca gtggcagact ggggtgtaca cgagcttcgg 2820
 gggcagctgg aggagtgccg tgggcgctgg gactccgcc tgtgcctgga ggaacgcgac 2880
 tggctgcctg gaaaaacct ctttgagaac ctgtgggcct cggcttatgg cagccgcaag 2940
 acgctgtttg tgctggccca cacggaccgg gtcagtggct tcttgcgcg cagcttcctg 3000
 ctggcccagc agcgctctgt ggaggaccgc aaggacgtcg tgggtctggt gatcctgagc 3060
 cctgacggcc gccgctcccg ctacgtgcgg ctgcgcagc gcctctgccg ccagagtgtc 3120
 ctctctggc cccaccagcc cagtggctcag cgcagcttct gggcccagct gggcatggcc 3180
 ctgaccaggg acaaccacca cttctataac cggaacttct gccagggacc cacggccgaa 3240
 tagccgtgag ccggaatcct gcacggtgcc acctccacac tcacctacc tctgcctgcc 3300
 tggcttgacc ctcccctgct cgctccctc accccacacc tgacacagag ca 3352

<210> 18
 <211> 1032
 <212> PRT
 <213> Homo sapiens

<400> 18

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln
 1 5 10 15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
 20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu
 35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn
 50 55 60

Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp
 65 70 75 80

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp
 85 90 95

58182US002.ST25.txt

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met
 100 105 110

Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
 115 120 125

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser
 130 135 140

Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser
 145 150 155 160

Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly
 165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro
 180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
 195 200 205

Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr
 210 215 220

Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu
 225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
 245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe
 260 265 270

Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly
 275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe
 290 295 300

Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu
 305 310 315 320

Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu
 325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala
 340 345 350

58182US002.ST25.txt

His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu
 355 360 365
 Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu
 370 375 380
 Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met
 385 390 395 400
 Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly
 405 410 415
 Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu
 420 425 430
 Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu
 435 440 445
 Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu
 450 455 460
 Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser
 465 470 475 480
 Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser
 485 490 495
 His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val
 500 505 510
 Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu
 515 520 525
 Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu
 530 535 540
 Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly
 545 550 555 560
 Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr
 565 570 575
 Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser
 580 585 590
 Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn
 Page 45

Page 46

58182US002.ST25.txt

Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp
 850 855 860

Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln
 865 870 875 880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu
 885 890 895

Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp
 900 905 910

Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr
 915 920 925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser
 930 935 940

Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
 945 950 955 960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg
 965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
 980 985 990

Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln
 995 1000 1005

Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg
 1010 1015 1020

Asn Phe Cys Gln Gly Pro Thr Ala Glu
 1025 1030

<210> 19
 <211> 3002
 <212> DNA
 <213> Homo sapiens

<400> 19
 gtggcttggt attcactggc aggtttcaga catttagatc tttcttttaa tgactaacac 60
 catgcctatc tgtggagaag ctggcaacat gtcacacctg gaaattgttt ttcaacatta 120
 atactattat ttggcagtaa tccagattgc ttttgccacc aacctgaaga catatagagg 180
 cagaaggaca ggaataattc tatttgtttc ctgttttgaa acttccatct gtaaggctat 240
 caaaaggaga tgtgagagag ggtattgagt ctggcctgac aatgcagttc ttaaaccaaa 300

58182US002.ST25.txt

ggtccattat gcttctcctc tctgagaatc ctgacttacc tcaacaacgg agacatggca	360
cagtagccag cttggagact tctcagccaa tgctctgaga tcaagtcgaa gacccaatat	420
acagggtttt gagctcatct tcatcattca tatgaggaaa taagtggtaa aatccttgga	480
aatacaatga gactcatcag aaacattttac atattttgta gtattgttat gacagcagag	540
ggtgatgctc cagagctgcc agaagaaagg gaactgatga ccaactgctc caacatgtct	600
ctaagaaagg ttcccgagag cttgacccca gccacaacga cactggattt atcctataac	660
ctcctttttc aactccagag ttcagatttt cattctgtct ccaaactgag agttttgatt	720
ctatgccata acagaattca acagctggat ctcaaacct ttgaattcaa caaggagtta	780
agatatttag atttgtctaa taacagactg aagagtgtaa cttgggtattt actggcaggt	840
ctcaggtatt tagatctttc ttttaatgac tttgacacca tgcctatctg tgaggaagct	900
ggcaacatgt cacacctgga aatcctaggt ttgagtgggg caaaaataca aaaatcagat	960
ttccagaaaa ttgctcatct gcatctaaat actgtcttct taggattcag aactcttcct	1020
cattatgaag aaggtagcct gccatctta aacacaacaa aactgcacat tgttttacca	1080
atggacacaa atttctgggt tcttttgctg gatggaatca agacttcaaa aatattagaa	1140
atgacaaata tagatggcaa aagccaattt gtaagttatg aaatgcaacg aaatcttagt	1200
ttagaaaaatg ctaagacatc ggttctattg cttaataaag ttgatttact ctgggacgac	1260
cttttcctta tcttacaatt tgtttgcat acatcagtg aacactttca gatccgaaat	1320
gtgacttttg gtggtgaaggc ttatcttgac cacaattcat ttgactactc aaatactgta	1380
atgagaacta taaaattgga gcatgtacat ttcagagtgt ttacattca acaggataaa	1440
atctatttgc ttttgaccaa aatggacata gaaaacctga caatatcaaa tgcacaaatg	1500
ccacacatgc ttttcccgaa ttatcttacg aaattccaat atttaaattt tgccaataat	1560
atcttaacag acgagttgtt taaaagaact atccaactgc ctcaattgaa aactctcatt	1620
ttgaatggca ataaactgga gacactttct ttagtaagtt gctttgctaa caacacaccc	1680
ttggaacact tggatctgag tcaaaatcta ttacaacata aaaatgatga aaattgctca	1740
tggccagaaa ctgtggtcaa tatgaatctg tcatacaata aattgtctga ttctgtcttc	1800
aggtgcttgc ccaaaagtat tcaaataactt gacctaaata ataaccaa at ccaaactgta	1860
cctaaagaga ctattcatct gatggcctta cgagaactaa atattgcatt taattttcta	1920
actgatctcc ctggatgcag tcatttcagt agactttcag ttctgaacat tgaaatgaac	1980
ttcattctca gccatctct ggattttgtt cagagctgcc aggaagttaa aactctaaat	2040
gcgggaagaa atccattccg gtgtacctgt gaattaaaaa atttcattca gcttgaaaca	2100
tattcagagg tcatgatggt tggatggtca gattcataca cctgtgaata ccctttaaac	2160

58182US002.ST25.txt

ctaaggggaa ttaggttaaa agacgttcat ctccacgaat tatcttgcaa cacagctctg	2220
ttgattgtca ccatttgtgt tattatgcta gttctggggg tggctgtggc cttctgctgt	2280
ctccactttg atctgccctg gtatctcagg atgctaggtc aatgcacaca aacatggcac	2340
agggttagga aaacaaccca agaacaactc aagagaaatg tccgattcca cgcattttatt	2400
tcatacagtg aacatgattc tctgtgggtg aagaatgaat tgatcccaa tctagagaag	2460
gaagatgggt ctatcttgat ttgcctttat gaaagctact ttgaccctgg caaaagcatt	2520
agtgaaaata ttgtaagctt cattgagaaa agctataagt ccatctttgt tttgtctccc	2580
aactttgtcc agaatgagt gtgccattat gaattttact ttgccacca caatctcttc	2640
catgaaaatt ctgatcatat aattcttata ttactggaac ccattccatt ctattgcatt	2700
cccaccaggt atcataaact gaaagctctc ctggaaaaaa aagcatactt ggaatggccc	2760
aaggataggc gtaaatgtgg gcttttctgg gcaaaccctc gagctgctat taatgttaat	2820
gtattagcca ccagagaaat gtatgaactg cagacattca cagagttaaa tgaagagtct	2880
cgaggttcta caatctctct gatgagaaca gattgtctat aaaatcccac agtccttggg	2940
aagttgggga ccacatacac tgttgggatg tacattgata caacctttat gatggcaatt	3000
tg	3002

<210> 20
 <211> 811
 <212> PRT
 <213> Homo sapiens

<400> 20

Met Arg Leu Ile Arg Asn Ile Tyr Ile Phe Cys Ser Ile Val Met Thr
 1 5 10 15

Ala Glu Gly Asp Ala Pro Glu Leu Pro Glu Glu Arg Glu Leu Met Thr
 20 25 30

Asn Cys Ser Asn Met Ser Leu Arg Lys Val Pro Ala Asp Leu Thr Pro
 35 40 45

Ala Thr Thr Thr Leu Asp Leu Ser Tyr Asn Leu Leu Phe Gln Leu Gln
 50 55 60

Ser Ser Asp Phe His Ser Val Ser Lys Leu Arg Val Leu Ile Leu Cys
 65 70 75 80

His Asn Arg Ile Gln Gln Leu Asp Leu Lys Thr Phe Glu Phe Asn Lys
 85 90 95

Glu Leu Arg Tyr Leu Asp Leu Ser Asn Asn Arg Leu Lys Ser Val Thr
 Page 49

58182US002.ST25.txt

100 105 110

Trp Tyr Leu Leu Ala Gly Leu Arg Tyr Leu Asp Leu Ser Phe Asn Asp
115 120 125

Phe Asp Thr Met Pro Ile Cys Glu Glu Ala Gly Asn Met Ser His Leu
130 135 140

Glu Ile Leu Gly Leu Ser Gly Ala Lys Ile Gln Lys Ser Asp Phe Gln
145 150 155 160

Lys Ile Ala His Leu His Leu Asn Thr Val Phe Leu Gly Phe Arg Thr
165 170 175

Leu Pro His Tyr Glu Glu Gly Ser Leu Pro Ile Leu Asn Thr Thr Lys
180 185 190

Leu His Ile Val Leu Pro Met Asp Thr Asn Phe Trp Val Leu Leu Arg
195 200 205

Asp Gly Ile Lys Thr Ser Lys Ile Leu Glu Met Thr Asn Ile Asp Gly
210 215 220

Lys Ser Gln Phe Val Ser Tyr Glu Met Gln Arg Asn Leu Ser Leu Glu
225 230 235 240

Asn Ala Lys Thr Ser Val Leu Leu Leu Asn Lys Val Asp Leu Leu Trp
245 250 255

Asp Asp Leu Phe Leu Ile Leu Gln Phe Val Trp His Thr Ser Val Glu
260 265 270

His Phe Gln Ile Arg Asn Val Thr Phe Gly Gly Lys Ala Tyr Leu Asp
275 280 285

His Asn Ser Phe Asp Tyr Ser Asn Thr Val Met Arg Thr Ile Lys Leu
290 295 300

Glu His Val His Phe Arg Val Phe Tyr Ile Gln Gln Asp Lys Ile Tyr
305 310 315 320

Leu Leu Leu Thr Lys Met Asp Ile Glu Asn Leu Thr Ile Ser Asn Ala
325 330 335

Gln Met Pro His Met Leu Phe Pro Asn Tyr Pro Thr Lys Phe Gln Tyr
340 345 350

58182US002.ST25.txt

Leu Asn Phe Ala Asn Asn Ile Leu Thr Asp Glu Leu Phe Lys Arg Thr
 355 360 365

Ile Gln Leu Pro His Leu Lys Thr Leu Ile Leu Asn Gly Asn Lys Leu
 370 375 380

Glu Thr Leu Ser Leu Val Ser Cys Phe Ala Asn Asn Thr Pro Leu Glu
 385 390 400

His Leu Asp Leu Ser Gln Asn Leu Leu Gln His Lys Asn Asp Glu Asn
 405 410 415

Cys Ser Trp Pro Glu Thr Val Val Asn Met Asn Leu Ser Tyr Asn Lys
 420 425 430

Leu Ser Asp Ser Val Phe Arg Cys Leu Pro Lys Ser Ile Gln Ile Leu
 435 440 445

Asp Leu Asn Asn Asn Gln Ile Gln Thr Val Pro Lys Glu Thr Ile His
 450 455 460

Leu Met Ala Leu Arg Glu Leu Asn Ile Ala Phe Asn Phe Leu Thr Asp
 465 470 475 480

Leu Pro Gly Cys Ser His Phe Ser Arg Leu Ser Val Leu Asn Ile Glu
 485 490 495

Met Asn Phe Ile Leu Ser Pro Ser Leu Asp Phe Val Gln Ser Cys Gln
 500 505 510

Glu Val Lys Thr Leu Asn Ala Gly Arg Asn Pro Phe Arg Cys Thr Cys
 515 520 525

Glu Leu Lys Asn Phe Ile Gln Leu Glu Thr Tyr Ser Glu Val Met Met
 530 535 540

Val Gly Trp Ser Asp Ser Tyr Thr Cys Glu Tyr Pro Leu Asn Leu Arg
 545 550 555 560

Gly Ile Arg Leu Lys Asp Val His Leu His Glu Leu Ser Cys Asn Thr
 565 570 575

Ala Leu Leu Ile Val Thr Ile Val Val Ile Met Leu Val Leu Gly Leu
 580 585 590

Ala Val Ala Phe Cys Cys Leu His Phe Asp Leu Pro Trp Tyr Leu Arg
 595 600 605

58182US002.ST25.txt

Met Leu Gly Gln Cys Thr Gln Thr Trp His Arg Val Arg Lys Thr Thr
 610 615 620

Gln Glu Gln Leu Lys Arg Asn Val Arg Phe His Ala Phe Ile Ser Tyr
 625 630 635 640

Ser Glu His Asp Ser Leu Trp Val Lys Asn Glu Leu Ile Pro Asn Leu
 645 650 655

Glu Lys Glu Asp Gly Ser Ile Leu Ile Cys Leu Tyr Glu Ser Tyr Phe
 660 665 670

Asp Pro Gly Lys Ser Ile Ser Glu Asn Ile Val Ser Phe Ile Glu Lys
 675 680 685

Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro Asn Phe Val Gln Asn Glu
 690 695 700

Trp Cys His Tyr Glu Phe Tyr Phe Ala His His Asn Leu Phe His Glu
 705 710 715 720

Asn Ser Asp His Ile Ile Leu Ile Leu Leu Glu Pro Ile Pro Phe Tyr
 725 730 735

Cys Ile Pro Thr Arg Tyr His Lys Leu Lys Ala Leu Leu Glu Lys Lys
 740 745 750

Ala Tyr Leu Glu Trp Pro Lys Asp Arg Arg Lys Cys Gly Leu Phe Trp
 755 760 765

Ala Asn Leu Arg Ala Ala Ile Asn Val Asn Val Leu Ala Thr Arg Glu
 770 775 780

Met Tyr Glu Leu Gln Thr Phe Thr Glu Leu Asn Glu Glu Ser Arg Gly
 785 790 795 800

Ser Thr Ile Ser Leu Met Arg Thr Asp Cys Leu
 805 810

<210> 21
 <211> 215
 <212> DNA
 <213> Homo sapiens

<400> 21
 aaaaacaaaa catttgagaa acacggctct aaactcatgt aaagagtgca tgaaggaaag 60
 caaaaacaga aatggaaagt ggcccagaag cattaagaaa gtggaaatca gtatgttccc 120

58182US002.ST25.txt
tatttaaggc atttgcagga agcaaggcct tcagagaacc tagagcccaa gggttcagagt 180
cacccatctc agcaagccca gaagtatctg caata 215

<210> 22
<211> 36
<212> DNA
<213> Artificial

<220>
<223> 5' primer for human IFN-alpha promoter

<400> 22
acgagatcta agcttaaaac aaaacatttg agaaac 36

<210> 23
<211> 28
<212> DNA
<213> Artificial

<220>
<223> 3' primer for human IFN-alpha promoter

<400> 23
acgagatcta gatattgcag atacttct 28